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ACPA: anti-citrullinated protein antibody 
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BMM: bone marrow derived macrophage 
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catecholaminergic: signaling involving catecholamines as neurotransmitters 
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1 Introduction 
1.1 Rheumatoid arthritis 
1.1.1 Prevalence and current models of pathology  
Rheumatoid arthritis (RA) is a chronic inflammatory disease (CID) which mainly affects small interdigi-
tal, typically the proximal interphalangeal, metacarpophalangeal and wrist joints in hands, the metatar-
sophalangeal joints in the feet, and the knee joint (Aletaha et al., 2010; McInnes & Schett, 2011). 
Worldwide, about 1% of the population is diagnosed with RA (Firestein, 2003). If left untreated, pro-
gression of RA leads to articular damage, typically expressed by symptoms like swelling and reoccur-
ring pain at morning, and ultimately disability of affected joints, rendering this disease a socio-
economical threat to patients and the whole population (Aletaha et al., 2010; McInnes & O'Dell, 2010; 
McInnes & Schett, 2011). Moreover, due to the systemic and self-sustaining inflammatory nature of 
RA, the risk of developing secondary diseases related to the cardiovascular system, and insulin re-
sistance, metabolic syndrome, osteoporosis, fatigue and depression increases, all possible reasons 
for an overall increased mortality observed in RA (Aletaha et al., 2010; McInnes & Schett, 2011). 
In the last few decades genetic association studies revealed that rheumatoid arthritis is in fact an auto-
immune disease, based on the identification of many risk alleles which alone or in synergy with envi-
ronmental triggers (especially smoking) increase susceptibility of developing autoimmune mechanisms 
and eventually disease outbreak (McInnes & Schett, 2011): An important discovery was that the pres-
ence of circulating autoantibodies, like rheumatoid factor (RF) and ACPA (anti-citrullinated protein an-
tibody) which are diagnostic markers for RA, is not only highly associated with the human leukocyte 
antigen (HLA)-DRB1 gene but even more so with a certain amino acid sequence (QKRAA motif) within 
the HLA-DRB1 protein, a major histocompatibility complex class II (MHCII) molecule (Firestein, 2003; 
McInnes & O'Dell, 2010; McInnes & Schett, 2011). Further it was demonstrated that the conversion of 
arginine residues to citrulline residues in endogenous proteins by exogenous noxae like smoking or 
exposition to certain pathogens, is highly associated with antigen presentation to T cells via HLA-
DRB1 and production of autoantibodies like RF or ACPA which are directed against these modified 
endogenous proteins (Firestein, 2003; McInnes & O'Dell, 2010; McInnes & Schett, 2011). These ob-
servations suggest that the adaptive immune system is a key player in the accrual of auto-reactivity of 
the immune system in RA (Firestein, 2003; McInnes & O'Dell, 2010; McInnes & Schett, 2011). Howev-
er, it was found that this could not be the sole reason for the pathogenesis, since there are RA patients 
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who do not display expression of circulating antibodies like RF or ACPA, although disease severity is 
mostly more intense in RF- or ACPA-positive patients (McInnes & Schett, 2011). There is strong evi-
dence that the innate immune system is as well involved in the pathogenesis of RA since antagonizing 
of certain cytokines like tumor necrosis factor (TNF) or interleukin (IL)-6, which are mainly produced by 
cells of the innate immune system like macrophages, has been proven to be highly effective in the 
therapy of many RA patients (Firestein, 2003; McInnes & O'Dell, 2010; McInnes & Schett, 2011; van 
Vollenhoven, 2009). In general, leukocytes, cells of both innate and adaptive immune system, are 
attracted to the inflamed joint by a chemotactic gradient and eventually migrate into the joint (Firestein, 
2003; McInnes & Schett, 2011). Enhanced adhesion of these immune cells to the vessels near the 
joint then promotes accumulation and invasion into inflamed tissues adjacent to these vessels 
(Firestein, 2003; McInnes & Schett, 2011). The synovial membrane is a special connective tissue sur-
rounding a joint and producing the synovial fluid, which has the purpose of lubrication and exchange of 
nutrients and metabolites in chondrocytes of articular cartilage (Haywood & Walsh, 2001; Levick, 
1995). In RA, the synovial membrane typically displays signs of inflammation (synovitis) including pro-
liferation, increased angiogenesis, altered lymphatic vessels and activation of the endothelium which 
facilitates the attraction and accumulation of circulating leukocytes (McInnes & Schett, 2011). This has 
been shown by the accumulation of macrophages, mast cells and natural killer (NK) cells, T and B-cell 
aggregates in the synovial membrane as well as neutrophil granulocytes in the synovial fluid 
(Firestein, 2003; McInnes & Schett, 2011). Together with activated fibroblast like synoviocytes (FLS), 
these immune cells generate a self-sustaining pro-inflammatory milieu by producing pro-inflammatory 
cytokines like TNF, IL-1b, IL-6 and IL-17, reactive oxygen and nitrogen species, and matrix degrading 
proteases like matrix metallo-proteinases (MMPs). Since anti-inflammatory and inhibitory mechanisms 
especially signaling of regulatory T (Treg) cells, endogenous tissue inhibitors of metalloproteinases 
(TIMPs) and inhibitory cytokines increasingly fail during pathogenesis of RA, this local inflammatory 
milieu prevails and ultimately leads to breakdown of articular cartilage by invasive FLS and activity of 
MMPs thereby forming typical aggressive, pannus like structures (Firestein, 2003; McInnes & Schett, 
2011). In addition to the degradation of articular cartilage, also erosions of articular bone are typical 
features of active RA, which seem to occur already soon after diagnosis and are detected in most RA 
patients (McInnes & Schett, 2011). Erosions of bone are uniquely mediated by osteoclasts, a special-
ized multinucleated cell type, which arises from the monocyte /macrophage linage of cells and is pre-
sent in circulating blood and in the bone marrow (Herman et al., 2008a; Udagawa et al., 1990). Under 
the influence of certain locally enhanced cytokines, especially M-CSF (macrophage colony stimulating 
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factor) and RANK (receptor activator of nuclear factor kappa B) ligand, and further augmented by TNF, 
IL-1, IL-6, IL-17, these cells fuse and ultimately differentiate into active multinucleated bone resorbing 
osteoclasts (Herman et al., 2008a). Under physiological conditions, bone turnover is tightly balanced 
between bone resorption by osteoclasts and bone formation by osteoblasts (Herman et al., 2008a). In 
RA however, this homeostasis is disturbed by local conditions, which favor generation and activity of 
osteoclasts and simultaneously inhibit activity of bone forming osteoblasts (Herman et al., 2008a; 
McInnes & Schett, 2007; Schett, 2011). Continuous resorption of bone can lead to a direct contact 
between the normally mutually separated bone marrow and the synovial fluid which contains activated 
immune cells, invasive FLS and inflammatory cytokines, leading to inflammation of the bone marrow 
(osteitis) (McInnes & Schett, 2011). However, there is still debate whether synovitis or osteitis and 
subsequent bone resorption precede initial steps of RA pathogenesis (Kleyer & Schett, 2014; 
McQueen & Naredo, 2011; Schett & Firestein, 2010). 
Eventually, erosions of articular bone, degradation of articular cartilage and an expanding, destructive 
inflamed hypertrophic synovial membrane including an aggressive pannus lead to a loss of joint integ-
rity and function, pain and immobility (Firestein, 2003; McInnes & Schett, 2011). The high systemic 
inflammatory load in established active RA further increases the risk of developing secondary, espe-
cially cardiovascular diseases and ultimately increases mortality (McInnes & O'Dell, 2010; McInnes & 
Schett, 2011). Hence, a diagnosis as early as possible is of upmost importance, distinguishing joints 
typically affected by osteoarthritis (OA) from joints typically affected by RA and further differentiating 
RA subgroups, as this has an impact on the treatment and disease development (Aletaha et al., 2010; 
McInnes & O'Dell, 2010; McInnes & Schett, 2011). 
1.1.2 Diagnosis and current treatment of RA 
The current RA classification criteria of the American College of Rheumatology (ACR, formerly Ameri-
can Rheumatism Association) and the European League Against Rheumatism (EULAR) emphasize 
the importance of early diagnosis in order to initiate also an early aggressive treatment, ideally achiev-
ing remission of disease in the shortest possible period of time (Aletaha et al., 2010). Diagnosis first 
involves the definite recognition of swelling in joints caused by inflammation in the synovial membrane 
(synovitis) and possibly erosions in articular bone which occur early in RA (Aletaha et al., 2010; 
McInnes & Schett, 2011). Detection of these alterations should be confirmed by x-ray radiography, 
ultrasound, or magnet resonance imaging (MRI) (Aletaha et al., 2010). Definite synovitis and/or ten-
derness in at least one joint that can not be explained better otherwise renders a patient eligible for 
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diagnosis of RA (Aletaha et al., 2010). To diagnose a possible RA status of such an individual patient, 
an objective scoring further involves the number of affected joints, detection of auto-antibodies RF 
and/or ACPA (see 1.1.1), abnormalities in erythrocyte sedimentation rates and levels of C-reactive 
protein (CRP), and duration of observed symptoms (Aletaha et al., 2010). While these criteria include 
the latest knowledge for the best and most early diagnosis of RA, many other scoring systems for 
evaluating current RA disease activity in patients have evolved in order to compare different treat-
ments and to monitor and ensure efficacy of treatment (McInnes & O'Dell, 2010). Some of these are 
relative scores, describing the percentage of improvement (e.g. ACR20, 20% improvement), which 
renders them valuable in clinical trials but unsuitable in clinical practice (McInnes & O'Dell, 2010). 
Others are of absolute nature and highly accurate (DAS, disease activity score) (McInnes & O'Dell, 
2010). Therefore, and owing to the fact that disease activity should be monitored regularly to ensure 
appropriate treatment, several other means of disease activity assessment are being used in practice, 
which do not require special equipment and can be acquired in a fast and relatively easy manner 
(McInnes & O'Dell, 2010). 
It has been widely accepted that upon diagnosis initial and first line treatment of RA should rapidly 
begin with a monotherapy using disease modifying anti-rheumatic drugs (DMARDs) which includes 
most importantly methotrexate (MTX), leflunomide, sulfasalazine, hydroxychloroquin and glucocorti-
coids (McInnes & O'Dell, 2010; van Vollenhoven, 2009). Methotrexate and leflunomide are regarded 
as anti-metabolites with MTX antagonizing purine synthesis and leflunomide antagonizing pyrimidine 
synthesis, which is considered especially effective in lymphocytes (van Vollenhoven, 2009). The anti-
inflammatory action of MTX is at least in part thought to be mediated by signaling via adenosine (van 
Vollenhoven, 2009). Although both drugs, MTX and leflunomide, display similar efficacy to safety rati-
os, MTX became the most widely used DMARD, probably also due to better compliance and lower 
costs (van Vollenhoven, 2009). Breakthrough in therapy for DMARDs was also due to the fact that 
DMARDs can be combined in therapy if needed, and that certain combinations are superior to MTX 
monotherapy (van Vollenhoven, 2009). According to current guidelines and several studies, initial 
therapy should start off early with administration of MTX only or MTX combined with low dose gluco-
corticoids (Aletaha et al., 2010; McInnes & O'Dell, 2010), rendering MTX as the ‘anchor drug’ in mono- 
and combinational therapy (Aletaha et al., 2010; Pincus et al., 2003). In cases in which RA patients do 
not respond to MTX or adverse side effects are observed, alternatives like leflunomide or sulfasala-
zine, an anti-inflammatory drug should be tried in monotherapy, before a step up to certain combina-
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tions of DMARDs is required (McInnes & O'Dell, 2010; van Vollenhoven, 2009). Other DMARDs like 
gold containing drugs, ciclosporin A (an immunosuppressive agent), certain antibiotics, and azathio-
prine (a cytostatic drug) are still used in certain cases but due to a higher risk of adverse side effects 
they are not considered first line medications (McInnes & O'Dell, 2010; van Vollenhoven, 2009). The 
anti-malaria drug hydroxychloroquine, which seems to interfere with antigen presentation, was shown 
to be effective especially in combination with MTX or sulfasalazine, and to decrease the risk of devel-
oping diabetes, while displaying only relatively mild adverse effects (McInnes & O'Dell, 2010; van 
Vollenhoven, 2009). The use of glucocorticoids has experienced a renaissance as a first line DMARD 
since it was found that administration of low doses during initial treatment is effective in limiting joint 
damage in RA and has the advantage of a relatively fast response, in contrast to most other DMARDs 
(McInnes & O'Dell, 2010; van Vollenhoven, 2009). However, it is still controversial whether or how fast 
administration of glucocorticoids in combination with MTX or alternative DMARDs should be tapered 
off in order to avoid adverse effects of glucocorticoids or be kept up to achieve remission of RA in the 
long run, also paying respect to the inadequate release of endogenous glucocorticoids (cortisol in 
humans, corticosteron in rodents) in arthritis (McInnes & O'Dell, 2010; Straub et al., 2013; van 
Vollenhoven, 2009). 
With gaining knowledge about the cellular and molecular signaling pathways in RA in recent decades, 
new classes of substances were developed and approved for treating RA. The need for new sub-
stances emerged due to a growing number of patients who were not responding to mono or combina-
tional therapy at all, experienced adverse effects, or response to a combination of several DMARDs 
was inadequate (McInnes & O'Dell, 2010; van Vollenhoven, 2009). The relatively new class of sub-
stances, currently simply referred to as ‘biologicals’ due to their antibody or protein related molecular 
structure and (micro-)biological way of production (van Vollenhoven, 2009), mainly exploits its efficacy 
by interference with cytokine signaling pathways which play a major role in activation of leukocytes, 
synovial fibroblasts and osteoclasts (McInnes & Schett, 2011). Since TNF plays a central role in acti-
vating many cells and inflammatory pathways relevant to RA (Firestein, 2003; McInnes & Schett, 
2007; McInnes & Schett, 2011; Schett et al., 2013) several antibodies to TNF (adalimumab, certoli-
zumab, golimumab, infliximab) and a fusion receptor (etanercept) have been approved for treatment of 
RA (McInnes & O'Dell, 2010; van Vollenhoven, 2009) and have shown efficacy even in other chronic 
inflammatory disorders (Schett et al., 2013). Interestingly, all TNF inhibitors display similar efficacy to 
risk ratios (McInnes & O'Dell, 2010). The broad success and the high efficacy highlight the crucial 
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roles of TNF in these cytokine networks and led to development of further molecules targeting the IL-6 
pathway (tocilizumab, an anti-IL-6 receptor antibody) and IL-1 pathway (anakinra, an IL-1 receptor 
antagonist), due to both cytokines being important in signaling of leukocytes, synovial fibroblasts, and 
also osteoclasts (McInnes & Schett, 2007; Schett, 2011). Yet, anakinra proved only modest efficacy in 
the treatment of RA but seems to be more efficient in treating other inflammatory diseases like juvenile 
idiopathic arthritis and gout (McInnes & Schett, 2007; Schett et al., 2013; van Vollenhoven, 2009).  
Moreover, also specific inhibition of B-cells with the help of a monoclonal antibody directed against 
CD20 (rituximab), which is believed to decrease production of auto-antibodies like RF and ACPA, and, 
hence, is especially useful in respective serum positive patients, has been approved (McInnes & 
Schett, 2007; McInnes & O'Dell, 2010; van Vollenhoven, 2009). Also specific inhibition of T-cell co-
stimulation, a critical step of T-cell activation, by the CTLA-4 ligand abatacept has shown efficacy, e.g. 
in patients resistant to anti-TNF therapy (McInnes & Schett, 2007; McInnes & O'Dell, 2010; van 
Vollenhoven, 2009). 
Existing general guidelines and the treat-to-target of remission principle suggest a step up, escalating 
therapy regime in which after failure of mono or combination therapy with DMARDs, first TNF inhibiting 
biologicals should be used or added, followed by more specialized agents like tocilizumab, rituximab 
and abatacept if needed or anti-TNF therapy fails (McInnes & O'Dell, 2010; van Vollenhoven, 2009). 
Effective and safe therapy has to be routinely monitored and adjusted if needed depending on each 
patient’s individual medical records, which includes presence and treatment of co-morbidities, pres-
ence of serum auto-antibodies like RF or ACPA, efficacy or failure of DMARD mono or combination 
therapy, and step-up therapy with biologicals including possible adverse effects (McInnes & O'Dell, 
2010; van Vollenhoven, 2009). 
Recent research focused on intracellular signal transduction pathways, especially, on targets like Ja-
nus kinases (JAKs) and tyrosine kinases, which belong to cell surface receptors that trigger such in-
tracellular signaling cascades often involved in activating expression of pro-inflammatory mediators 
(McInnes & Schett, 2011). This led to the recent approval of tofacitinib, a molecule which is thought to 
inhibit JAK1 and subsequent STAT (signal transducer and activator of transcription) 1 and 3 signaling, 
and was shown to decrease gene expression of MMPs and chemokines in synovial fibroblasts of RA 
patients (Boyle et al., 2014). Despite promising preclinical results, p38-mitogen activated protein ki-
nase (MAPK) inhibitors, and the phosphodiesterase (PDE)-4 inhibitor apremilast, which inhibits the 
degradation of the intracellular signaling molecule cyclic adenosine-mono-phosphate (cAMP) and, 
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thus, TNF production, displayed disappointing results in clinical studies with RA patients (McInnes & 
Schett, 2011; Genovese et al., 2015; McCann et al., 2010; McInnes & O'Dell, 2010). Further, two dis-
advantages of biologicals especially regarding TNF inhibitors remain: Compared to DMARDs they are 
costly and adverse effects include serious, potentially fatal infections and an increased risk of develop-
ing lymphoma and other malignancies (McInnes & Schett, 2007; McInnes & O'Dell, 2010; van 
Vollenhoven, 2009). Other potential drug targets still under trial include B-cell activating factors, the 
pro-inflammatory interleukin 17, RANK ligand, and other kinases (McInnes & Schett, 2011). 
Due to developing therapy resistance after a certain time or adverse effects seen in some patients 
under treatment with DMARDs and biologicals, there still remains need for exploiting further pathways 
involved in RA pathogenesis (Lipsky, 2009; McInnes & O'Dell, 2010; van Vollenhoven, 2009). Such 
attempts also include targeting the peripheral nervous system (PNS), particularly since activation of 
certain (α7 subunit containing) nicotinic acetylcholine receptors (α7nAChR) in the periphery was sug-
gested to elicit anti-inflammatory pathways (Waldburger et al., 2008; Wang et al., 2003) and these 
receptors were discovered on the surface of macrophages in the spleen (Rosas-Ballina et al., 2011) 
and on fibroblasts and macrophages in the synovium (Forsgren, 2012; van Maanen et al., 2009b; 
Waldburger et al., 2008; Westman et al., 2009). Exact mechanisms of observed effects are still unclear 
as proposed models have changed several times (reviewed in (Martelli et al., 2014a)) and hence are 
subject of debate (Martelli et al., 2014a; Martelli et al., 2014b; Nance & Sanders, 2007; Pongratz & 
Straub, 2013; Straub et al., 2013). However, pharmacological stimulation of α7nAChR and electrical 
stimulation of the vagus nerve, the anatomically biggest nerve of the cholinergic PNS, has shown 
promising results in experimental arthritis (Levine et al., 2014; van Maanen et al., 2009a) and it was 
suggested that exploiting these pathways might be a therapy option in treatment of RA (Koopman et 
al., 2011; Koopman et al., 2014; Levine et al., 2014; van Maanen et al., 2009c). 
1.2 The peripheral nervous system in RA 
Apart from a disturbed signaling of the CNS and the endocrine system with inadequate composition of 
sex hormones and inadequate provision of endogenous glucocorticoids during arthritis (Straub et al., 
2013; Del Rey et al., 2010; Wolff et al., 2014; Straub, 2014), it has been long established that the pe-
ripheral nervous system (PNS) locally modulates outbreak and progression of RA (Levine et al., 1987; 
Pongratz & Straub, 2013). RA typically displays a symmetrical involvement of arthritic joints in the 
extremities, meaning that with increasing number of affected joints over time mostly also bilateral af-
fection of extremities is observed (Aletaha et al., 2010; Firestein, 2003). The most striking proof of an 
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involvement of the PNS in RA is the observation that patients who suffer from hemiplegia display RA 
mostly in the non-paralyzed hand, whereas the hemiplegic hand is typically spared from RA (Keyszer 
et al., 2004). To verify this clinical observation, sciatic and femoral nerves were severed in an animal 
model of experimental arthritis and indeed, denervated limbs were protected from developing arthritis 
(Stangenberg et al., 2014). Yet, the exact mechanisms like an involvement of the microvasculature 
and the immune system, as suggested by the interesting findings of Stangenberg et al., and how they 
are controlled by the PNS still remain to be further elucidated (Rabquer & Koch, 2014; Schaible & 
Straub, 2014). 
However, drawing more specific conclusions from these observations can be potentially misleading 
because hemiplegia and experimental transection of limb nerves most likely affects all different kinds 
of nerves since the PNS is divided into different parts according to its function: The sensory nervous 
system which mainly transmits pain, inflammatory related stimuli and danger signals from the periph-
ery to the brain (afferent function), the parasympathetic nervous system, which is often referred as 
‘rest and digest’ promoting nervous system, but the role of which in arthritis is still relatively unclear, 
and its counterpart the sympathetic nervous system, which in regards to arthritis was shown to in-
fluence blood flow, vascular permeability and local immune processes (reviewed in (Pongratz & 
Straub, 2013; Schaible & Straub, 2014)). The sympathetic nervous system can be further subdivided 
into an (nor)-adrenergic catecholaminergic and a cholinergic branch, based on which neurotransmit-
ters convey the signals in the post-ganglionic part of the connection between CNS and periphery 
(Ernsberger & Rohrer, 1999). The main neurotransmitters present in the sensory nervous system and 
important for the efferent function of sensory nerves are substance P (SP) and calcitonin gene related 
peptide (CGRP) (Pongratz & Straub, 2013), and detection of SP is commonly used to identify sensory 
nerve fibers. Important neurotransmitters of the (nor)-adrenergic part of the sympathetic PNS are 
norepinephrine (NE, also known as noradrenaline) and its co-transmitters neuropeptide Y (NPY) and 
adenosine (Pongratz & Straub, 2013; Straub, 2012). Detection of sympathetic nerve fibers containing 
these neurotransmitters is commonly accomplished by staining tyrosine hydroxylase (TH) or dopamine 
beta hydroxylase (DBH), as these two proteins are key enzymes in the biosynthesis of the catechola-
mines dopamine and NE, and hence are expressed in sympathetic nerves of CNS and PNS (Tekin et 
al., 2014). Cholinergic parts of the PNS convey signals via the main cholinergic and eponymous neu-
rotransmitter acetylcholine (ACh) and vasoactive intestinal peptide (VIP), a typical co-transmitter of 
cholinergic nerve endings (Ernsberger & Rohrer, 1999). These nerves are commonly detected by 
1.2 The peripheral nervous system in RA 
9 
 
staining the ACh synthesizing enzyme choline acetyltransferase (ChAT), the vesicular acetylcholine 
transporter (VAChT) or VIP protein (Duong et al., 2002; Eiden et al., 2004; Erickson et al., 1994; 
Ernsberger & Rohrer, 1999; Guidry & Landis, 1998; Schafer et al., 1998). 
Interestingly, all of these systems including the respective neurotransmitters and their receptors are 
present in bone (Figure 1) and take part in the control of physiological bone turnover differently influ-
encing bone formation by osteoblasts and bone resorption by osteoclasts (Aitken et al., 2009; 
Bjurholm et al., 1988; Eimar et al., 2013; Elefteriou, 2005; Hill & Elde, 1991; Hohmann et al., 1986; 
Imai & Matsusue, 2002; Lerner & Persson, 2008; Persson & Lerner, 2011; Suzuki et al., 1998).
 
Figure 1. Schematic drawing of a joint in physiological, healthy condition (left) and during 
arthritis (right). Involved cells and the different parts of the peripheral nervous system are highlighted. 
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In RA however, this neuronal control is disturbed, and activity of osteoclasts is enhanced also due to 
inflammatory cytokines, leading to characteristic focal bony erosions (Braun & Zwerina, 2011; McInnes 
& Schett, 2007; Schett, 2011). Further, presence of sympathetic noradrenergic nerve fibers and senso-
ry nerve fibers has been also demonstrated in the synovial tissue of humans and mice (reviewed in 
(Pongratz & Straub, 2013)). However, so far not much is known about a possible direct innervation by 
cholinergic nerve fibers in joints, although expression of VAChT-positive nerve fibers was recently 
shown in femora from mice (Bajayo et al., 2012) and rats (Lips et al., 2014) in addition to VIP contain-
ing nerve fibers in bone (Asmus et al., 2000; Bjurholm et al., 1988; Hill & Elde, 1991; Hohmann et al., 
1986; Sisask et al., 1996) and synovial tissue of the rat (Bjurholm et al., 1990). Moreover, in addition to 
the α7nAChR protein, mRNA transcripts of several parts of the cholinergic machinery like ChAT or the 
high affinity choline transporter (ChT), were shown to be expressed in the synovial tissue of arthritis 
patients (Beckmann et al., 2015; Forsgren, 2012). However, no direct innervation by the PNS was 
shown, and the authors concluded that in the joint a local cell based, non-neuronal cholinergic system 
(NNCS) might be present (Beckmann & Lips, 2013), similar to such a system, which was shown by 
Kawashima and coworkers to exist in leukocytes (Kawashima & Fujii, 2004; Kawashima et al., 2012). 
Further and in contrast to noradrenergic sympathetic innervation, nothing is known about a possible 
cholinergic innervation of joints in mice and humans during the course of arthritis. 
Importantly, innervation by peripheral nerves is not static per se but under certain circumstances 
shows neuroplasticity (Pongratz & Straub, 2013). This phenomenon has been demonstrated in the 
joints of arthritic mice and RA patients, which during arthritis display a loss of sympathetic nerve fibers 
while sensory innervation increases (Pongratz & Straub, 2013). These observations have been mainly 
addressed to the action of elevated levels of the unspecific nerve growth factor NGF and semaphorins 
3C and F, which are nerve repellent factors specific for noradrenergic sympathetic nerve fibers (Aloe 
et al., 1993; Fassold et al., 2009; Miller et al., 2004). Interestingly, a local loss of sympathetic nora-
drenergic nerve fibers is not exclusive to arthritic joints but has been shown also in other inflammatory 
settings like in the colon wall of Crohn’s disease patients (Straub et al., 2008a), in chronic Charcot foot 
in diabetes (Koeck et al., 2009), in the myocardium after heart failure (Parrish et al., 2010), in inflamed 
pancreatic islands of diabetic rats (Mei et al., 2002), and in secondary lymphoid organs of arthritic rats 
and mice (Lorton et al., 2005; Lorton et al., 2009; Straub et al., 2008b). 
Regarding the relationship between inflammation and the PNS during arthritis, a time-dependent, bi-
modal action was demonstrated for the noradrenergic sympathetic PNS as it acts pro-inflammatory in 
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early stage experimental arthritis and anti-inflammatory in later stages of arthritis (Harle et al., 2005; 
Harle et al., 2008). In contrast to this early pro-inflammatory effect, which was attributed to enhanced 
cell mobilization, action of certain pro-inflammatory T-cells and antibody production by B-cells, it is still 
relatively unclear how this late anti-inflammatory effect might be conveyed since noradrenergic sympa-
thetic nerve fibers are seemingly lost (Pongratz & Straub, 2013). This has the consequence that, due 
to lower concentrations of NE and higher receptor affinity of NE towards α-AR (adrenoceptors), also 
receptor signaling changes from a predominantly β-AR based signaling, which may act pro- and anti-
inflammatory, to a predominantly α-AR based signaling, thought to elicit mainly pro-inflammatory ef-
fects (Pongratz & Straub, 2013). It was suggested that this late anti-inflammatory effect at least in part 
might be due to locally emerging catecholamine-producing cells, which partially substitute input from 
sympathetic nerve endings (Jenei-Lanzl et al., 2015; Capellino et al., 2012; Miller et al., 2000; Miller et 
al., 2002), and an elevated production of the anti-inflammatory cytokine interleukin 10 in B-cells 
(Pongratz et al., 2012; Pongratz & Straub, 2013). 
Efferent signaling of sensory nerve fibers and its main neurotransmitters SP and CGRP is generally 
regarded as pro-inflammatory in arthritis (Lorton et al., 2000; Uematsu et al., 2011) as they induce 
general inflammatory symptoms like vasodilatation, reddening and edema (Pongratz & Straub, 2013), 
proliferation of T and B cells (Laurenzi et al., 1989; Payan et al., 1983) and in the case for SP stimu-
lates osteoclast formation and activity (Kojima et al., 2006; Lerner & Persson, 2008; Wang et al., 
2009). 
Anti-inflammatory effects of cholinergic signaling have been described for the activation of nicotinic 
acetylcholine receptors, especially by activation of the α7nAChR on immune cells and synoviocytes 
(Kawashima et al., 2012; van Maanen et al., 2009a; van Maanen et al., 2010; Waldburger et al., 2008; 
Wang et al., 2003; Yoshikawa et al., 2006), but signaling of ACh via certain muscarinic receptors can 
also elicit pro-inflammatory pathways (Eglen, 2006; Fujii et al., 2003; Fujii et al., 2008; Kawashima et 
al., 2012). Further, anti-inflammatory effects have been reported for VIP (Delgado et al., 2001; 
Delgado et al., 2003; Delgado & Ganea, 2008; Gonzalez-Rey et al., 2006; Gonzalez-Rey & Delgado, 
2008). Since presence of these systems has been identified in arthritis (Delgado et al., 2008a; van 
Maanen et al., 2009b; Waldburger et al., 2008; Westman et al., 2009), consequently it was suggested 
not to enhance general cholinergic signaling via ACh, but to specifically target the α7nAChR and VIP 
receptors to exploit their anti-inflammatory potential (Bencherif et al., 2011; Delgado et al., 2002; 
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Delgado et al., 2008b; Delgado & Ganea, 2008; Gonzalez-Rey et al., 2007; Koopman et al., 2011; van 
Maanen et al., 2009c). 
In general however, whether signaling of different parts of the PNS results in activation of pro- or anti-
inflammatory pathways, critically depends on local neurotransmitter concentration provided by the 
respective nerve endings and the locally present different neurotransmitter receptors (Pongratz & 
Straub, 2013), both of which themselves may change during developmental stages (Sisask et al., 
1996) and diseases such as RA (Pongratz & Straub, 2013). 
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1.3 Cholinergic transition of sympathetic nerve fibers 
Under certain circumstances noradrenergic sympathetic nerve fibers are able to change towards a 
cholinergic phenotype of sympathetic nerve fibers (see Figure 2), the process of which is mostly re-
ferred to as sympathetic transition or cholinergic transition / differentiation of sympathetic nerve fibers 
and neurons (reviewed in (Ernsberger & Rohrer, 1999)). 
 
Figure 2. Scheme of catecholaminergic-to-cholinergic transition of sympathetic nerve fibers. 
 
This phenomenon was first described by Landis and co-workers, who were investigating the innerva-
tion of developing sweat glands (Landis & Keefe, 1983; Landis et al., 1988), and was later also found 
in the periosteum (Asmus et al., 2000; Asmus et al., 2001), and in the myocardium (Kanazawa et al., 
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2010; Parrish et al., 2010; Yamamori et al., 1989) (reviewed in (Kimura et al., 2012). Molecular mech-
anisms of these phenomena are highly complex and several pathways involved in these processes 
have been studied: Generally, there seem to be target-independent (initial induction of cholinergic 
properties) and target-dependent (later trans-differentiation after target contact) pathways which can 
drive the acquisition of cholinergic properties in sympathetic neurons (Apostolova & Dechant, 2009; 
Stanke et al., 2006). Regarding sweat glands, there are studies supporting both, a target-dependent 
pathway, in which sympathetic neurons show cholinergic properties only after target contact (Guidry & 
Landis, 1998), or an early target-independent pathway, suggesting a neuronal co-expression of both 
noradrenergic and cholinergic properties before reaching the sweat glands (Schütz et al., 2008). 
While in the heart leukemia inhibitory factor (LIF) was identified as the responsible factor driving this 
transition (Yamamori et al., 1989), the exact nature of the sweat gland specific transition factor still 
remains to be determined as several promising candidate cytokines belonging to the glycoprotein-130 
(gp130) family of cytokines like LIF, ciliary neurotrophic factor (CNTF) and cardiotrophin-1 (CT-1) have 
already been ruled out. This was demonstrated in vivo by anti-cytokine treatment or mice lacking ge-
netic information for one or more candidate cytokines. Both approaches did not inhibit the sympathetic 
transition in sweat glands, which is a hint for the existence of a further yet undiscovered cytokine 
(Francis et al., 1997; Habecker et al., 1995; Francis & Landis, 1999; Rao & Landis, 1990; Rao et al., 
1993). Still, the molecule that induces sympathetic transition in sweat glands seems to act via the 
gp130/ LIF-receptor-β receptor complex and, thus, could be a novel member of the gp130 cytokine 
class (Habecker et al., 1997; Apostolova & Dechant, 2009). While it was established that signaling via 
the gp130/LIF-receptor-β and following activation of the JAK/STAT3 (Janus Kinase, signal transducer 
and activator of transcription) pathway plays a central role for the transition (Bamber et al., 1994; 
Geissen et al., 1998; Habecker et al., 1997), there are also studies reporting secretory responsiveness 
in gp130 deficient mice and cholinergic reactivity in sympathetic neurons not induced by the LIF-
receptor β. This raised the question whether secretory response is solely mediated via cholinergic 
signaling or if possible remnants of catecholaminergic signaling still can elicit a response (Stanke et 
al., 2000; Stanke et al., 2006). 
Other pathways than the classical LIF-receptor-β/STAT activation influencing cholinergic development 
have been discovered: Loy et al. and Apostolova et al. demonstrated that the p38-mitogen activated 
kinases (p38-MAPK) subtypes α and β independently from the JAK/STAT pathway promote cholinergic 
properties by activating the nuclear matrix protein Satb2. Upon activation, Satb2 binds to the choliner-
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gic gene locus and up-regulates expression of cholinergic markers while at the same time down-
regulating expression of catecholaminergic properties (Apostolova et al., 2010; Loy et al., 2011). To 
add further complexity, it was also shown that in most sympathetic cholinergic neurons, which are 
positive for VIP, the GDNF (glial cell-line derived neurotrophic factor) family receptor GFR-alpha2 is 
co-expressed. In their respective target tissues, namely sweat glands and periosteum, gene expres-
sion of NRTN (neurturin), a ligand for GFR-alpha2 was detected. In GFR-alpha2 knock-out mice, in-
nervation of sweat glands as such was unchanged but the density of cholinergic fibers was drastically 
reduced and even completely absent in the periosteum (Hiltunen & Airaksinen, 2004). Therefore, 
NRTN signaling via GFR-alpha2 also seems to play an important role in the acquisition and mainte-
nance of cholinergic innervation in sweat glands. Additionally, the growth factors NGF (nerve growth 
factor) and NT-3 (neurotrophin-3), which are typically released by the target tissues critically influence 
induction, regulation and survival of a sympathetic catecholaminergic phenotype (Francis et al., 1999; 
Francis & Landis, 1999). NT-3 signaling additionally seems to be influenced by the p75
NTR
 receptor 
(Brennan et al., 1999). Even for neurotransmitter molecules, such as catecholamines, an involvement 
in sympathetic transition of sweat glands was shown: While a direct activation of adenylyl cyclase 
(AC), an important signaling component after G-protein coupled receptor (GPCR) activation, by for-
skolin supports the process of the sympathetic transition to a cholinergic phenotype, a blockade of 
alpha and beta adrenoceptors inhibits the latter. Seemingly, the sympathetic axons release NE, trig-
gering the up-regulation and release of the transition factor from the sweat glands, which in turn elicits 
the neuron to transform itself into a neuron with a cholinergic phenotype. In the same study, the sweat 
gland derived transition factor activity was absent in sympathectomized mice compared to control mice 
(Habecker & Landis, 1994). In a further study, TH deficient mice were treated with L-DOPA (the pro-
genitor of dopamine in catecholamine synthesis), which increased the number of active sweat glands 
in these mice (Tian et al., 2000). The role of acetylcholine has as well been investigated: Treatment of 
young rats with atropine, a nonselective ACh antagonist or with a selective antagonist against the 
muscarinic (gland) subtype of ACh receptors delayed the development of secretory responsiveness 
and hence also sympathetic transition to a cholinergic phenotype. Treatment of adult rats with atropine 
resulted in a complete loss of function. When rats were selectively denervated, the following loss of 
secretory responsiveness could be rescued by pilocarpine, a muscarinic ACh receptor agonist (Grant 
et al., 1995). 
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1.4 Hypothesis and study aim 
This study’s aim was to elucidate such a possible transition of sympathetic nerve fibers to nerve fibers 
with cholinergic properties in highly inflamed tissues of arthritic mice and in synovial tissue from pa-
tients with arthritis, based on following hypothesis: The observed loss of TH in sympathetic catechol-
aminergic nerve fibers during arthritis is in fact not due to a loss of the entire sympathetic nerve fiber, 
but instead due to a sympathetic transition of the latter to a cholinergic phenotype. 
The rationale for this thesis is founded on the well described loss of sympathetic nerve fibers in arthri-
tis (see 1.2.) and the fact that such a loss of sympathetic nerve fibers is also being observed in tissues 
like developing sweat glands and the periosteum that show the phenomenon of sympathetic transition 
(Asmus et al., 2000; Asmus et al., 2001; Landis et al., 1988; Landis, 1996). Furthermore, the presence 
of cytokines capable of inducing this transition, like LIF (see above) and oncostatin M (OSM) (Rao et 
al., 1992), has been demonstrated in the synovium of RA patients ((Hui et al., 1997; Lotz et al., 1992) 
reviewed in (Richards, 2013). 
This possible transition mediated by cytokines like LIF might resemble another part in the concept of 
an “anti-inflammatory cholinergic pathway” (Wang et al., 2003), which is also being proposed for 
treatment of arthritis (see 1.2). The exact mechanisms of this pathway(s), however, especially the in-
volvement and connection between noradrenergic sympathetic nerves in secondary lymphoid organs 
like the spleen, the cholinergic vagus nerve (Borovikova et al., 2000; Koopman et al., 2014; Rosas-
Ballina et al., 2011; Wang et al., 2003), and the anti-inflammatory mechanisms of α7nAChR activation 
still remain controversial (reviewed in (Martelli et al., 2014a; Martelli et al., 2014b; Pongratz & Straub, 
2013)). 
  
2.1 Overview of chemicals and labware 
17 
 
2 Patients, materials and methods 
2.1 Overview of chemicals and labware 
An overview of the devices, chemicals and antibodies in use for this study is given in table 1, table 2 
and table 3, respectively. Details of the patients under study and of ELISA kits for proteome analysis 
are given in separate tables (tables 4, 5, and 6, respectively). 
Table 1. Devices in use for this study. 
Device Company Details Purpose 
iMark Microplate reader, Mi-
croplate reader imaging soft-
ware 
Bio-Rad, USA Microplate 
manager soft-
ware version 
6.2 
ELISA measurement and 
analysis 
Fluorescence microscope, 
Visiview imaging software 
Leica, Germany Vis-
itron GmbH, Germa-
ny 
- Immunofluorescence 
microscopy, bright field 
microscopy 
Axiovision fluorescence mi-
croscope, Axiovision imaging 
software 
Zeiss, Germany Axiovision 
software ver-
sion 4.8 
Immunofluorescence 
microscopy, bright field 
microscopy 
STEMI, stereo microscope Zeiss, Germany - Dissection, ganglia prepa-
ration 
Nanodrop 2000 spectropho-
tometer 
Thermo scientific, 
USA 
Software ver-
sion 1.4.2 
Cell culture, BMM, RNA 
quantification 
Bioanalyzer 2100 series Agilent Technologies, 
USA 
B.02.08.SI648 
(SR2) 
Cell culture BMM, RNA 
quality analysis 
ChemiDoc Imager, ChemiDoc 
Imager software Image Lab 
Bio-Rad, USA Image Lab 
version 4.01 
Cytokine profiling, imag-
ing, image analysis 
Cryotome Leica biosystems, 
Germany 
- Histology 
Ultra turrax dispersant Ika, Germany T-10 Immunization 
Image J Wayne Rasband, 
National Institutes of 
Health, USA 
Image J ver-
sion 1.46 
Immunofluorescence 
microscopy, image analy-
sis 
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Table 2. Chemicals in use for this study. 
Chemical / Kit Company Cat.no. Purpose 
Erythrocyte lysis buffer Qiagen, Germany 79217 Cell culture of BMM 
Macrophage colony stimulat-
ing factor (M-CSF) 
Peprotech, USA 315-02 Cell culture of BMM 
Culture dish, 35mm Corning, USA 430166 Cell culture of BMM 
Cell lifter Corning, USA 3008 Cell culture of BMM 
RANK ligand R&D systems, Ger-
many 
462-TEC-010 Cell culture of BMM 
Acid phosphatase, leukocyte 
TRAP kit 
Sigma Aldrich, USA 387A Cell culture of BMM 
Dispase II, neutral protease 
grade II 
Roche Diagnostics, 
Germany 
04942078001 Cell culture of ganglia 
Nerve growth factor Sigma Aldrich, USA N0513 Cell culture of ganglia 
8well µslide Ibidi, Germany 80826 Cell culture of ganglia 
Poly-D-lysine solution Sigma Aldrich, USA 6407 Cell culture of ganglia 
Leukemia inhibitor factor (LIF) Applichem, Germany A8831 Cell culture of ganglia 
Progesterone Sigma Aldrich, USA P8783 Cell culture of ganglia 
Tissue inhibitor of metallopro-
teinase 1 (TIMP-1) 
R&D Systems, Ger-
many 
980-MT Cell culture of ganglia 
Culture inserts Ibidi, Germany 80209 Cell culture of ganglia, co-
culture 
6well culture plate Corning, USA 3516 Cell culture, BMM 
Trypan blue Sigma Aldrich, USA T8154 Cell culture, BMM 
Minimum essential medium 
eagle 
Sigma Aldrich M4526 Cell culture, BMM 
Gene Chip® Mouse Gene 2.0 
ST 
Affymetrix, USA 902118 Cell culture, BMM, gene 
expression analysis 
Cytokine profiler R&D Systems, Ger-
many 
ARY006 Cell culture, BMM, prote-
ome analysis 
RNeasy mini kit Qiagen, Germany 74104 Cell culture, BMM, RNA 
isolation 
Arginine-glycine-aspartate-
serine tetrapeptide (RGDS) 
Cayman Chemical, 
USA 
15359 Cell culture, ganglia 
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Biglycan R&D Systems, Ger-
many 
8128-CM Cell culture, ganglia 
F12 Nut mix + Glutamax me-
dium 
Gibco/Life technolo-
gies, USA 
31765-027 Cell culture, ganglia 
RPMI 1640 medium Sigma Aldrich, USA R8758 Cell culture, lymph node 
cells 
Hematoxylin solution Merck-Millipore, USA 1.09249 Histology, staining 
Eosin solution Merck-Millipore, USA 1.09844 Histology, staining 
1,9-dimethyl-methylene blue 
(DMMB) 
Sigma Aldrich, USA 341088 Histology, staining 
Ethylenediaminetetraacetic 
acid 
Sigma Aldrich, USA ED-1kg Histology, tissue decalcifi-
cation 
Rapid decalcifying solution 
(RDO) 
Apex Engineering, 
USA 
- Histology, tissue decalcifi-
cation 
Tissue Tek Sakura Finetek, 
Netherlands 
4583 Histology, tissue embed-
ding 
Formalin Merck-Millipore, USA 1039991000 Histology, Tissue fixation 
Chicken collagen type II Sigma Aldrich, USA C9301 Immunization 
Mycobacterium tuberculosis 
H37Ra, heat inactivated 
Difco Laboratories, 
USA 
231141 (3114-
33) 
Immunization 
Freund adjuvant, incomplete Sigma Aldrich, USA F5506 Immunization 
Freund adjuvant, complete Sigma Aldrich, USA F5881 Immunization 
Bovine collagen type II MD Bioproducts, 
Switzerland 
804001-sol Immunization 
Fluorescent mounting medium Dako, Denmark S3023 Immunofluorescence 
microscopy 
Triton X-100 Sigma Aldrich, USA X-100 Immunofluorescence 
microscopy 
4',6-Diamidino-2-phenylindol Sigma Aldrich, USA D9542 Immunofluorescence 
microscopy, cell nuclei 
staining 
Bovine serum albumin Sigma Aldrich, USA A7906 Immunofluorescence 
microscopy, staining 
Fetal calf serum Sigma Aldrich, USA F0804 Immunofluorescence 
microscopy, staining 
Donkey serum, donor herd Equitech-BIO Inc., 
USA 
SD-0100HI Immunofluorescence 
microscopy, staining 
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Goat serum, donor herd Sigma Aldrich, USA G6767 Immunofluorescence 
microscopy, staining 
3,3’ diaminobenzidine (DAB) Vector Labs, USA SK4105 Immunohistochemistry 
 
Table 3. Antibodies in use for this study. 
Antibody Company Cat.no. Purpose 
Anti-VAChT, rabbit polyclonal Synaptic Systems, 
Germany 
139103 Immunofluorescence 
microscopy 
Anti-TH, guinea pig polyclonal Synaptic Systems, 
Germany 
213004 Immunofluorescence 
microscopy 
Anti-TH, rabbit polyclonal Chemicon/Millipore, 
USA 
AB152 Immunofluorescence 
microscopy 
Anti-VIP, rabbit polyclonal Abcam, UK 22736 Immunofluorescence 
microscopy 
Anti-α7nAChR , rabbit poly-
clonal 
Abcam, UK 10096 Immunohistochemistry 
Alexa Fluor 546 labeled goat 
anti-rabbit antibody 
Life Technologies, 
USA 
A-11010 Immunofluorescence 
microscopy 
Alexa Fluor 594 labeled don-
key anti-rabbit antibody 
Life Technologies, 
USA 
A-21207 Immunofluorescence 
microscopy 
Alexa Fluor 488 labeled goat 
anti-guinea pig antibody 
Life Technologies, 
USA 
A-11073 Immunofluorescence 
microscopy 
Control immunoglobulin frac-
tion, rabbit 
Dako, Denmark X0903 Immunohistochemistry 
Goat anti-rabbit HRP conju-
gated antibody 
Pierce/Thermo Sci-
entific, USA 
32260 Immunohistochemistry 
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2.2 Patients and tissue samples 
Patients were informed about the studies and gave written consent. The Ethics Committee of the Uni-
versity of Regensburg approved the studies (Official reference numbers 13-101-0135 and 13-101-
0031). Synovial tissue was obtained from patients with OA and RA, who underwent knee joint re-
placement surgery. Samples from distal or proximal interphalangeal finger joints including bone, carti-
lage, and connective tissue like synovial tissue but not dermal skin were obtained from patients with 
OA and RA who received finger joint arthrodesis surgery. Diagnosis of RA was based on the estab-
lished criteria according to the American College of Rheumatology (formerly, the American Rheuma-
tism Association) (Arnett et al., 1988). Patients who received finger joint arthrodesis surgery are char-
acterized in table 4. Patients who received total knee replacement surgery are described in table 5. 
Table 4. Characteristics of patients under study for cholinergic markers VAChT and VIP in finger 
joints. *One patient was investigated on the left and right side. Data are given as means ± SEM, per-
centages in parentheses, and ranges in brackets. 
 Osteoarthritis of finger joints Rheumatoid arthritis of finger joints 
Number 6 4 
Age, yr 64.2 ± 11.4 [50-79] 63.8 ± 4.9 [59-70] 
Gender male / female 1 / 5 (17/83) 1 / 3 (25/75) 
Indication for surgery 6, finger joint arthrodesis 4, finger joint arthrodesis 
Affected joint, proximal / distal 5 / 1 3 / 1 
Affected side, right / left 5 / 2* 1 / 3 
 
Table 5. Characteristics of patients under study for cholinergic markers VAChT and VIP in synovial 
tissue of the knee. Data are given as means ± SEM, percentages in parentheses, and ranges in 
brackets. 
 Osteoarthritis of the knee Rheumatoid arthritis of the knee 
Number 44 24 
Age, yr 67.7 ± 8.9 [51-86] 65.9 ± 9.4 [50-84] 
Gender male / female 20 / 24 (45/55) 6 / 18 (25/75) 
Indication for surgery 44, total knee arthroplasty 24, total knee arthroplasty 
Affected side, right / left 23 / 21 13 /11 
C-reactive protein, mg/L 2.5 ± 2.1 [0.1-7.2] 9.5 ± 12.4 [0.5-45.0] 
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Directly after surgery, samples of knee synovial tissue and finger joint samples were fixed in 3.7% 
formalin (Merck-Millipore, Billerica, Massachusetts) for 24 hr. Finger joint samples which partially con-
tained bone tissue were decalcified for 7 – 14 d in a solution containing 20% EDTA (Ethylenedia-
minetetraacetic acid, Sigma Aldrich) buffered to a pH of 7.2. Both, samples of knee synovial tissue and 
samples from finger joints were dehydrated for 24 hr in phosphate buffered saline (PBS) containing 
20% sucrose. After dehydratation, samples were then transferred into a cylinder made of aluminum foil 
containing Tissue Tek (Tissue Tek, Sakura Finetek, Zoeterwoude, The Netherlands) and quick frozen 
floating on liquid nitrogen. The Tissue Tek blocks containing the embedded samples were then stored 
at -20°C. 
2.3 Animals, arthritis induction and sample collection 
Male mice (8-10 weeks) were housed in cages, 5 animals per cage, were fed standard laboratory 
chow and water ad libitum, and exposed to a daily 12 hr light / 12 hr dark cycle (Elevage Janvier, Le 
Genest St. Isle, France). Male animals were chosen to exclude possible interference of the hormonal 
cycle in female mice with the outcome of the experiments. C57Bl/6J mice were immunized according 
to a published protocol (Inglis et al., 2008) (see also below, 2.4, 2.5). Briefly, heat inactivated myco-
bacterium tuberculosis H37Ra (Difco Laboratories, Detroit, Michigan) was given to incomplete Freund 
adjuvant (Sigma Aldrich, St. Louis, USA) at a concentration of 3.3mg/mL (solution A). Chicken colla-
gen type II (Sigma Aldrich, St. Louis, USA) was dissolved overnight in 0.1M acetic acid to obtain a 
solution of 4mg/mL (solution B). Equal amounts of solution A and B were emulsified with the help of a 
dispersing instrument (T10 Ultraturrax, Ika Werke, Staufen, Germany), and a total of 100µL of this 
emulsion was intradermally injected into the tail base of each mouse. Analogously, arthritis was also 
induced in male DBA1/J mice (8-10 weeks of age, Elevage Janvier, Le Genest St. Isle, France) with 
bovine collagen type II (MD Bioproducts, Egg b. Zurich, Switzerland) emulsified in an equal amount of 
complete Freund adjuvant (Sigma Aldrich). 
All experiments with mice were conducted according to local institutional and governmental regula-
tions for animal use (Government of the Oberpfalz, Az. 54-2532.1-25/13 and Az. 54-2532.1-04/13). 
Progression of collagen type II-induced arthritis (CIA) was continuously monitored by evaluating clini-
cal signs. At days 14, 21, 25, 28, 35, 40, and 55 after immunization, C57Bl/6J mice were killed and 
limbs were collected. After fixation for 24 hr with 3.7% formalin (Merck-Millipore, Billerica, Massachu-
setts), samples were decalcified with rapid decalcifying solution (RDO, Apex Engineering, Illinois). 
After 24 hr in PBS containing 20% sucrose, samples were embedded in Tissue Tek (Tissue Tek, Sa-
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kura Finetek, Zoeterwoude, The Netherlands), quick frozen floating on liquid nitrogen, and stored at -
20°C. 
2.4 Histology and immunofluorescence staining 
For investigation of neuronal innervation, 10 -12 µm thick cryo-sections were taken with the help of a 
cryostat (Leica biosystems, Wetzlar, Germany). After air-drying, the sections were rehydrated in PBS 
for 20 min. Hematoxylin-eosin (HE) staining was performed to evaluate overall structure and, particu-
larly, bony erosions in the joints of arthritic mice. Histological scoring of arthritic mouse joints included 
evaluation of erosions in bone, degradation of cartilage, inflammation of synovial and joint surrounding 
tissue, and infiltration of immune cells into the joint cavity. In addition, in human finger joint samples, 
staining with a 0.1% aqueous solution of 1,9-dimethyl-methylene blue (DMMB) was performed to 
evaluate possible loss of cartilage. 
Sections from mice and patients were blocked for 45 min (bovine serum albumin, fetal calf serum, goat 
serum and 0.3% Triton X-100). After washing with PBS, both sections were incubated for 3-12 hr with 
a primary antibody against VAChT (cholinergic marker, 1:750, cat.no. 139103, Synaptic Systems 
GmbH, Göttingen, Germany). In mice, limb sections were incubated with a primary antibody against 
TH in a separate staining process of neighboring tissue sections (1:500, cat.no. AB152, Chemicon, 
Temecula, California). In human samples, finger joint and knee synovial sections were incubated with 
a primary antibody against vasoactive intestinal peptide (VIP) in a separate staining process (1:500, 
cat.no. 22736, abcam, Cambridge, UK). In human finger joint samples, neighboring sections were also 
stained for TH in a separate staining process (cat.no. AB152, Chemicon). 
After washing, sections were incubated with an Alexa Fluor 546 conjugated secondary antibody 
(1:500, cat.no. A-11010, goat anti rabbit IgG, Molecular Probes) to achieve immunofluorescent staining 
of cholinergic (VAChT+ or VIP+) and sympathetic catecholaminergic (TH+) nerve fibers. After an incu-
bation time of 90 min, sections were washed, and slides were subsequently mounted with fluorescent 
mounting medium (Dako, Glostrup, Denmark). 
The numbers of TH+ sympathetic catecholaminergic, VAChT+ cholinergic, and VIP+ cholinergic nerve 
fibers per square millimeter were determined by averaging the number of stained nerve fibers in 17 
randomly selected high power fields of view (typical bead chain structure with at least four separated 
beads along the axon, minimum length 50 µm, determined by a micrometer eyepiece). Positive nerve 
fiber staining was controlled by incubating tissue without primary antibodies or with immunoglobulin-
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matched control antibodies, which always yielded a negative result. General performance of anti-
VAChT and anti-TH antibody was checked by pre-incubation with the respective blocking peptide. 
Possible presence of the α7-subtype-containing nicotinic acetylcholine receptor (α7nAChR) in fibro-
blast like synoviocytes (FLS) from knee synovial tissue obtained from OA patients was tested by stain-
ing formalin fixed FLS with an rabbit polyclonal antibody raised against a peptide containing the amino 
acids 22-71 from human α7nAChR (cat.no. ab10096, abcam). FLS were first blocked for 45 min (bo-
vine serum albumin, fetal calf serum, goat serum and 0.3% Triton X-100) and then treated with a 3% 
solution of hydrogen peroxide for 10 min. The stock solution (1mg/mL) of the antibody and a control 
immunoglobulin fraction from rabbit (cat.no. X0903, Dako, 20mg/mL) were diluted 1:500 and 1:10,000 
respectively. FLS were stained overnight at 4° Celsius. After washing with PBS and 0.3% Triton X-100, 
FLS were incubated in a 1:500 dilution of a secondary goat anti rabbit antibody conjugated with horse-
radish peroxidase (HRP) for one hour (cat.no. 32260, Pierce/Thermo Scientific). After washing, cells 
were then incubated with a solution of 3,3’ diaminobenzidine (DAB) according to the manufacturer’s 
protocol (cat.no. SK4105, Vector Labs). 
2.5 Generation of osteoclast progenitor cells 
Generation of osteoclast progenitor (OCP) cells from bone marrow-derived macrophages (BMM) has 
been described (Takeshita et al., 2000). After sacrifice, femoral and tibial bone marrow was aseptically 
removed from healthy and arthritic male C57Bl/6J mice, subjected to lysis of erythrocytes (Buffer EL, 
Qiagen GmbH, Duesseldorf, Germany), and cells were cultured with 20ng/ml murine M-CSF (cat.no. 
315-02, Peprotech Inc., Rocky Hill, New Jersey) in a 35mm culture dish (cat.no. 430166, Corning In-
corporated, NY, USA). After 2 d, non-adherent cells were washed off with PBS, adherent cells were 
removed with a cell lifter (cat.no. 3008, Corning Incorporated), and cells were re-suspended in medi-
um with 20ng/ml M-CSF and 5ng/ml receptor activator of nuclear factor Kappa-B ligand (RANK ligand, 
cat.no. 462-TEC-010, R&D Systems, Wiesbaden, Germany). Viability and number of cells were de-
termined using the trypan blue exclusion method. In co-culture experiments with sympathetic ganglia 
20,000 BMM cells were seeded into each of the second compartment of the insert-equipped 8 well 
chamber slides (see 2.5 below). For the generation of whole RNA and cell culture supernatants 
150,000 cells were seeded into each well of a 6-well culture plate (see also 2.7 and 2.8). Poly-
nucleated (nuclei n≥3) and tartrate resistant acidic phosphate-positive cells appeared after 2 - 5 days 
after seeding and rated as OCP cells (Acid Phosphatase, Leukocyte TRAP Kit, cat.no. 387A, Sigma) 
(Figure 3). 
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In a separate set of experiments, OCPs were also obtained from healthy and arthritic DBA1/J mice to 
check a possible strain specificity of the co-culture experiments of sympathetic ganglia and OCP cells. 
 
Figure 3. Generation of osteoclast progenitor cells from bone marrow derived macrophages. 
A) Diagram delineating the process of obtaining osteoclast progenitors from BMM. B,C,D) Examples of 
multinucleated (cell nuclei in blue, DAPI stain) osteoclast progenitor cells (arrow heads) after 2 d dif-
ferentiation with M-CSF and RANKL, magnification x200. E,F,G) Examples of TRAP-positive (dark 
red/purple) osteoclast progenitor cells after 2 d differentiation with M-CSF and RANKL, magnification 
x100. Abbreviations: BMM, bone marrow derived macrophages; M-CSF, macrophage colony stimulat-
ing factor; RANKL, receptor activator of nuclear factor Kappa-B ligand; DAPI, 4',6-diamidino-2-
phenylindole; TRAP, tartrate resistant acid phosphatase (osteoclast marker). 
 
During the course of generating OCP cells from BMM for gene expression analysis and proteome 
profiling, two mentionable characteristics were observed: Firstly, the total amount of adherent BMM 
per animal which was harvested from the bone marrow of two tibiae and two femora and proliferated 
for two days with the help of M-CSF, was significantly higher in the group of arthritic animals compared 
to the group of healthy control mice (Figure 4A). Secondly, when BMM were differentiated for five 
consecutive days compared to 2 d, the size and number of giant multinucleated, TRAP-positive OCP 
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cells increased (Figure 4B). Yet, also more apoptotic events were observed, which were typically 
characterized by gaps and cell debris in the cell monolayer (Figure 4C), which had about the size of 
the giant OCPs as observed in (Figure 4B). 
 
Figure 4. Characteristics of bone marrow derived macrophages during proliferation and dif-
ferentiation. A) The total amount of BMM was counted after 2 d of proliferation with M-CSF. B) BMM 
differentiated for 5 d displayed increased size of multinucleated, TRAP+ (dark red/purple) osteoclast 
progenitor cells and showed enhanced signs of apoptosis (dashed lines, C). These observations (B,C) 
did not differ between cells from control and CIA animals. Numbers in parentheses indicate total num-
ber of samples analyzed. Box plots demonstrate the 10th (whisker), 25th, 50th (median), 75th, 90th 
(whisker) percentile. Abbreviations: CIA, collagen type II-induced arthritis; TRAP, tartrate resistant acid 
phosphatase. 
 
2.6 In-vitro experiments with sympathetic ganglia, co-culture 
with osteoclast progenitors, immunofluorescence staining 
and image analysis 
For the quantification of the fluorescence labeled markers TH and VAChT in mouse paravertebral 
sympathetic trunk ganglia an appropriate double staining technique had first to be established, also to 
exclude the possibility of false positive or high background staining. Here, successful double immuno-
fluorescence staining was first established in mouse colon formalin fixed and frozen tissue, which ex-
hibits both sympathetic TH expressing and cholinergic VAChT expressing nerve fibers and therefore 
was considered as a positive control for the double staining technique (Figure 5). This technique was 
then tested in mouse sympathetic ganglia and showed satisfactory results (Figure 5), being that Alexa 
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Fluor 488 indirectly labeled TH and Alexa Fluor 594 indirectly labeled VAChT could be separately ex-
cited and their fluorescence emission signal independently recorded via the use of fitting fluorescence 
filters in the microscope (Zeiss Axiovision). 
 
Figure 5. Establishing a double immuno fluorescence staining technique for tyrosine hy-
droxylase- and vesicular acetylcholine transporter-positive nerve fibers in mouse tissue. 
A,B,C,D,E) Double staining of TH and VAChT in mouse colon tissue (positive control) with A) showing 
an overview and B) showing a negative staining control, devoid of primary antibodies against TH and 
VAChT. C) Green fluorescence channel image depicting TH+ nerve fibers (green) and D) red fluores-
cence channel image depicting VAChT+ nerve fibers (red). E) Merged overlay image consisting of C) 
and D) showing distinct sets of nerve fibers (green=TH+, red=VAChT+) in submucosa and muscularis 
layers. F) Overview of a double staining of TH and VAChT in a mouse sympathetic trunk ganglion 
showing the soma in the center and radial outgrowth of TH+ (green) and VAChT+ (red) nerve fibers. 
G,H,I) Detailed images of sympathetic ganglia with depicting separate sets of TH+ and VAChT+ nerve 
fibers, demonstrating the specificity of the staining technique. Nerve fibers are stained in green (TH+) 
or red (VAChT+), cell bodies are counterstained with DAPI. Abbreviations: TH, tyrosine hydroxylase 
(key enzyme of catecholamine synthesis); VAChT, vesicular acetylcholine transporter (marker of cho-
linergic nerve fibers); DAPI, 4',6-diamidino-2-phenylindole. 
 
Culture of paravertebral sympathetic trunk ganglia obtained from mice has been described recently 
(Fassold et al., 2009; Fassold & Straub, 2010). Briefly, new born C57Bl/6J mice (postnatal day 2-4) 
were killed, and sympathetic trunk ganglia aseptically dissected under a stereo microscope (STEMI, 
Zeiss). After digestion and washing, ganglia were cultured for two days in medium with 100ng/ml 
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nerve growth factor (NGF) (cat.no. N0513, Sigma Aldrich) in 8-well chamber slides (8well µslide, ibidi 
GmbH, Martinsried, Germany), which were equipped with removable culture inserts made of silicone 
(cat.no. 80209, ibidi GmbH) (Figure 6). 
 
Figure 6. Scheme of the in-vitro co-culture system of sympathetic ganglia and osteoclast 
progenitor cells. A) Paravertebral sympathetic trunk ganglia are seeded into the poly-D-lysine coated 
half of a culture well which is physically separated from the uncoated half by a silicone insert. The 
uncoated half is being seeded with BMM. After 2 d culture period, sympathetic ganglia show a radial 
outgrowth of nerve fibers and BMM have differentiated into osteoclast progenitor cells in the presence 
of RANKL (B). C) Silicone inserts are removed and culture medium is being changed. Sympathetic 
ganglia and osteoclast progenitor cells are left in co-culture for 2 d. After 2 d, medium is removed, cells 
are washed, fixed with formalin and subsequently subjected to double immunofluorescence staining of 
TH and VAChT. Abbreviations: BMM, bone marrow derived macrophage; M-CSF, macrophage colony 
stimulating factor; RANKL, receptor activator of nuclear factor Kappa B ligand; TH, tyrosine hydrox-
ylase; VAChT, vesicular acetylcholine transporter. 
 
Half of the chamber divided by an insert was coated with a solution of poly-D-lysine (cat.no. 6407, 
Sigma Aldrich) to promote adhesion of sympathetic ganglia after seeding. The other half was seeded 
with arthritis-related cells of hematopoietic origin, which were obtained from either healthy or arthritic 
male mice (see above: 2.5, osteoclast progenitor cells, and 2.7, draining lymph node cells). After two 
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days, medium was aspirated, inserts were aseptically removed, and medium containing 25ng/ml of 
nerve growth factor, 20ng/mL M-CSF and 5ng/mL RANKL was added to the entire chamber.  
After a co-culture period of 2 d, medium was aspirated, the chambers were briefly washed with PBS, 
and cells were fixed with 3.7% formalin. After washing, cells were blocked for 45 min (bovine serum 
albumin, fetal calf serum, goat serum, donkey serum, and 0.3% Triton X-100). Sympathetic ganglia 
were double stained for 12 hr using antibodies against TH (1:750, cat.no. 213004, guinea pig polyclo-
nal, Synaptic Systems) and against VAChT (1:750, cat.no. 139103, rabbit polyclonal, Synaptic Sys-
tems). Alexa Fluor 488 and Alexa Fluor 594 conjugated secondary antibodies were used (both 1:500, 
donkey anti rabbit IgG, cat.no. A-21207, and goat anti guinea pig IgG, cat.no. A-11073, Molecular 
Probes). Cells were counterstained with 4',6-Diamidino-2-phenylindol (DAPI). Sympathetic ganglia 
were subsequently analyzed by fluorescence microscopy (Zeiss Axiovision, Zeiss, Jena, Germany). 
Double stained ganglia were photographed in 4 to 9 representative regions of the nerve fiber out-
growth area (not in the area of the soma of the ganglion). To determine the amount of positive pixels of 
the green fluorescence channel (= area of TH+ immunoreactivity, Alexa Fluor 488) and the red fluo-
rescence channel (= area of VAChT+ immunoreactivity, Alexa Fluor 594), the respective single chan-
nel images were analyzed by a color threshold function (Image J, Wayne Rasband, National Institutes 
of Health, USA, version 1.46). The same threshold value (126/255) which excluded false positive de-
tection of background-staining and only allowed for the exclusive detection of specifically stained 
nerve fibers was used for all images analyzed. The ratios of VAChT+ divided by TH+ pixels were cal-
culated for each image, which expresses the relative appearance of cholinergic to catecholaminergic 
sympathetic nerve fibers in this particular image. 
In order to test possible effects of leukemia inhibitory factor (LIF) on the ratio of VAChT+ to TH+ nerve 
fibers, separate experiments without any additional cells were conducted (using 100ng/ml of recombi-
nant mouse LIF; cat.no. A8831, AppliChem GmbH, Darmstadt, Germany). After 2 d of pure culture with 
100ng/ml of nerve growth factor, LIF was administered in the presence of 25 or 10ng/ml of nerve 
growth factor (Sigma) for another 2 d. In a subset of stimulation experiments with LIF, the culture me-
dium was devoid of progesterone (which is normally present in the culture medium for sympathetic 
ganglia at a concentration of 2x10
-7
M) to examine possible effects of sex steroids. 
Additionally, also TIMP-1 (tissue inhibitor of metalloproteinase 1), biglycan and fibronectin, of which 
the transcripts in OCPs from healthy mice were elevated (see 3.4.1), were tested in this assay. 
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In these experiments, first, the effects of fibronectin as a coating agent and of RGDS (arginine-glycine-
aspartate-serine tetra-peptide) as an agonist were tested. Due to the lack of murine full length protein, 
full length human fibronectin (cat.no. ab81743, abcam) was coated on top of self-coated poly-D-lysine 
(cat.no. 6407, Sigma Aldrich) coated 8-well chamber slides (ibidi) at a concentration of 10µg/mL in 
sterile PBS overnight at 4° Celsius. Sympathetic mouse ganglia were then cultivated in these slides for 
2 d in culture medium containing 100ng/mL NGF. 
For stimulation experiments with RGDS, TIMP-1 or biglycan, mouse sympathetic ganglia were cul-
tured in poly-D-lysine coated slides for 2 d in presence of 100ng/mL NGF and then after change of 
culture medium for another 2 d in presence of 25ng/mL NGF and 100µg/mL RGDS (cat.no. 3498, 
Tocris/R&D systems), 100ng/mL TIMP-1 (cat.no. 980-MT, R&D systems) or 3µg/mL biglycan (cat.no. 
8128-CM, R&D systems) respectively. 
2.7 Isolation of draining lymph node cells 
Draining lymph nodes were removed from healthy and arthritic C57Bl/6J mice. Inguinal draining lymph 
nodes, which are located near the hind limbs, were collected and aseptically processed through a 70 
µm cell strainer and, then, cells were cultured in RPMI 1640 culture medium (10% FCS, 1% penicillin / 
streptomycin, 20mM HEPES, 50µM beta-mercaptoethanol, and 0.01% ascorbic acid; all from Sigma). 
Viability and number of cells were determined using the trypan blue exclusion method. A total of 
20,000 cells were given to each of one half of well 8 well chamber slides analog to the set of experi-
ments with osteoclast progenitor cells (see above, 2.6). 
In a separate set of experiments, inguinal draining lymph node cells were also obtained from healthy 
and arthritic DBA1/J mice to check a possible strain specificity of the co-culture experiments of sympa-
thetic ganglia and draining lymph node cells. 
2.8 Gene expression profiling of osteoclast progenitor cells 
For gene expression analysis, arthritis was induced in male DBA1/J mice (8-10weeks, see also 2.2) 
since severity and incidence is more reproducible than in C57Bl/6 mice and, additionally, less animals 
are needed. BMM from arthritic mice (n=3) with similar high clinical arthritis scores in both hind limbs 
(8 score points or more per limb out of a maximum of 13 score points per limb) as well as BMM from 
healthy control animals (n=3) of the exact same age were isolated and cultured as described above 
(2.5). Within 2h before noon of the same day the bone marrow of all animals was collected since the 
circadian rhythm can have an impact on overall gene expression and, therefore, all samples had to be 
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obtained in a time-matched manner. After 2 d, adherent cells were collected and 150,000 cells were 
seeded into each well of a 6-well plate (cat.no.3516, Corning Incorporated, NY, USA), containing me-
dium with both M-CSF (20ng/ml) and RANK ligand (5ng/ml) (see above). After another 2 d, cells were 
lysed and whole RNA was isolated (RNeasy Mini Kit, Qiagen GmbH, Düsseldorf, Germany) according 
to the manufacturer’s protocol. Quantity and quality of whole RNA was tested with a Nanodrop 2000 
Spectrophotometer (Thermo Scientific, Wilmington, North Carolina) and a 2100 series Bioanalyzer 
(Agilent Technologies Inc., Santa Clara, California), respectively. Gene Chip® Mouse Gene 2.0 ST 
arrays were performed on the respective sets of whole RNA (cat.no. 902118, Affymetrix, Santa Clara, 
California). An authorized Affymetrix service provider (Kompetenzzentrum für Fluoreszente Bioanalytik 
(KFB), Regensburg, Germany) analyzed the array after validating the appropriate quality and quantity 
of RNA in the samples. Graphical color coded cluster image maps for selected genes taken from the 
microarray gene expression analysis were generated by using the public program CIMminer 
(http://discover.nci.nih.gov/cimminer/home.do , accessed Feb 15, 2015), provided by the National 
Cancer Institute (Scherf et al., 2000; Weinstein et al., 1997). For clustering, default settings (cluster 
rows, cluster columns, distance method: euclidean, cluster algorithm: average linkage) were used. 
In a separate experiment, BMM from arthritic DBA1/J mice (n=2) with similar high clinical scores in 
both hind limbs (see above) as well as cells from healthy control animals (n=2) with the same age 
were isolated and cultured the same way as described above except that the phase of differentiation 
with M-CSF and RANK ligand lasted for 5 d instead of 2 d (see above). This experiment was per-
formed to elucidate a possible influence of the duration of differentiation on the gene expression profile 
of OCP cells. 
2.9 Proteome profiling of osteoclast progenitor cells 
Since OCPs induced a shift of the ratio of cholinergic to catecholaminergic nerve fibers in co-culture 
with sympathetic ganglia and gene expression analysis of OCP cells revealed differences especially in 
cells differentiated for two days (given in 3. Results), respective cell culture supernatants were gener-
ated again and subsequently analyzed. For this purpose, bone marrow derived macrophages were 
obtained from highly arthritic (n=10) and age matched healthy control (n=10) DBA1/J male mice and 
were cultured and differentiated the same way as for the gene expression analysis of osteoclast pro-
genitor cells (2 d proliferation with M-CSF and 2 d differentiation with M-CSF and RANK ligand) de-
scribed above (2.8). After two days, supernatants were collected, pooled per animal, aliquoted and 
stored in cryotubes (Thermo Scientific) at -80°C until further analysis. 
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2.9.1 Proteome profile of osteoclast progenitor supernatants 
For the purpose of an overall semi-quantitative screening, supernatants generated by OCP cells from 
healthy (n=4) and arthritic (n=4) mice (see above, 2.9) were analyzed by the use of the mouse cyto-
kine proteome profiler technique according to the manufacturer’s protocol (cat.no. ARY006, R&D Sys-
tems, Wiesbaden, Germany). Briefly, respective supernatants were incubated on separate membranes 
each of which contains a total of 40 bound antibodies raised against 40 different proteins. The signal 
produced by a chemiluminescent color compound is proportional to the amount of protein bound to the 
membrane and was recorded with the use of a Bio-Rad Chemidoc Imager XRS (Bio-Rad, Hercules, 
CA, USA) and analyzed with the volume tools function of the Image Lab software (Image Lab, version 
4.0.1, Bio-Rad, USA). The mean pixel intensity per protein was then calculated relative to the mean 
pixel intensity of a positive control antibody present on every membrane set to 100%. The principle of 
this test is therefore semi-quantitative. 
2.9.2 ELISA measurements of osteoclast progenitor supernatants 
Suspected candidate proteins, which were up-regulated in the gene expression and proteome profiler 
analysis or which are known factors for sympathetic transition, were then quantitatively assayed with 
the use of individual ELISA tests: LIF, OSM, TIMP-1, Periostin/OSF-2 (osteoblast specific factor), pro-
gesterone, chemokine (C-C motif) ligand 2 (CCL2/MCP-1, monocyte chemoattractant protein-1), 
chemokine (C-C motif) ligand 3 (CCL3/MIP-1a, macrophage inflammatory protein-1a), chemokine (C-
C motif) ligand 5 (CCL5/RANTES, regulated upon activation, normally T-cell expressed and presuma-
bly secreted), chemokine (C-C motif) ligand 7 (CCL7/MCP-3, monocyte chemoattractant protein-3), 
chemokine (C-X-C motif) ligand 2 (CXCL2/MIP-2a, macrophage inflammatory protein-2a), chemokine 
(C-X-C motif) ligand 10 (CXCL10), chemokine (C-X-C motif) ligand 12 (CXCL12/SDF-1, stromal cell 
derived factor) were assayed. For detailed information about the ELISA see table 6 below. Assay 
ranges and sensitivities are given according to the manufacturer’s protocol. 
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Table 6. Details of the ELISA tests used for the analysis of the proteome of osteoclast progenitor 
cells from control and arthritic mice. 
Protein Synonym Manufacturer, cat. no. Range [pg/mL] Sensitivity [pg/mL] 
LIF  - R&D systems, MLF00 21.9 – 1,400 3.13 
OSM - R&D systems, DY495-05 6.25 - 400 6.25 
Periostin OSF-2 R&D systems, DY2955 93.8 - 6000 93.8 
TIMP-1 - R&D systems, MTM100 37.5 – 2,400 3.5 
Progesterone - IBL international, RE52231 300 – 40,000 45.0 
CCL2 MCP-1 R&D systems, DY479-05 3.91 - 250 3.91 
CCL3 MIP-1a R&D systems, DY450-05 7.81 - 500 7.81 
CCL5 RANTES R&D systems, DY478-05 31.2 – 2,000 31.2 
CCL7 MCP-3 Ebioscience, BMS6006INST 15.6 – 1,000 2.6 
CXCL2 MIP-2a R&D systems, DY452-05 15.6 – 1,000 15.6 
CXCL10 - R&D systems, DY466-05 62.5 – 4,000 62.5 
CXCL12 SDF-1 R&D systems, DY460 46.9 – 3,000 46.9 
 
2.10 Genetic analysis of the cholinergic gene locus 
The cholinergic gene locus in the murine and human genome comprises the genes for both ChAT 
(choline acetyltransferase, the acetylcholine synthesizing enzyme) and VAChT (vesicular acetylcholine 
transporter) (Eiden, 1998; Eiden et al., 2004; Erickson et al., 1994; Lawal & Krantz, 2013). Investiga-
tion of possible steroid binding sites (response elements) at the cholinergic gene locus in the human 
and mouse genome was carried out within the so-called interdisciplinary Z-project of the FOR696 of 
the University Hospital of Regensburg (DFG-funded research unit). Possible response elements for 
steroids were checked within the cholinergic gene locus, which is located on chromosome 14 in the 
mouse genome (Pubmed: ChAT gene ID: 12647) and chromosome 10 in the human genome (Pub-
med ChAT gene ID: 1103). In particular, possible binding sites within the VAChT gene 
(SLC18A3/Slc18a3, human/mouse respectively, solute carrier family 18 (vesicular monoamine), mem-
ber 3) which is located within the ChAT locus at 10q11.2 (human, Pubmed VAChT gene ID: 6572) and 
14 B; 14 19.4 cM (mouse, Pubmed VAChT gene ID: 20508) were checked. The Genomatix v2.4 (Mat-
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Inspector Release professional 8.0.5, March 2011, database version ElDorado 08-2011, Matrix Family 
Library Version 8.4 (June 2011)) software suite was used (Cartharius et al., 2005). 
2.11 Presentation of data and statistical analysis 
All data are given as mean  SEM. Box plots give the 10th, 75th, 50th (median), 25th, and 10th per-
centile. We compared group medians by the non-parametric Mann-Whitney U test (Sigma 
Plot/Windows, version 11.0.0.75, Systat Software Inc). Due to the explorative nature of the study, we 
did not adjust for multiple use of the same data. Log2-signals in gene expression analysis were com-
pared by using students’ t-test. Correlation analysis was performed using Spearman’s rank correlation 
(Sigma Plot). A p-value below 0.05 was considered as the significance level for all tests. Graphical 
interpretation of the signal intensities of selected genes in gene expression analysis is expressed in a 
color code, which is explained in the respective figure. 
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3 Results 
3.1 Density of catecholaminergic tyrosine hydroxylase-
positive and cholinergic vesicular acetylcholine trans-
porter-positive nerve fibers in mice 
With a latency of about 21 days post immunization, induction of collagen-induced arthritis in C57Bl/6 
mice clinically resulted in swelling and erythema in toes, metatarsus and ankle joints of forepaws and 
hindpaws. Histologically, when compared to respective joints from healthy control mice (Figure 7A), 
arthritic joints demonstrated erosions of articular bone, destruction of articular cartilage, and inflamma-
tion of synovial tissue (Figure 7B). Sympathetic TH-positive (TH+) nerve fibers were detected in joints 
(Figure 7C) and in adjacent connective tissue surrounding blood vessels (Figure 7D,E). Cholinergic 
nerve fibers positive for the vesicular acetylcholine transporter (VAChT+) were primarily detected in 
muscle and skin tissue of the paws (Figure 7F,G). 
 
Figure 7. Catecholaminergic and cholinergic nerve fibers in mice. A) Histology of a normal 
joint in the C57Bl/6 mouse. Characteristic smooth cartilage surface at day 0 before immunization. B) 
Histology of arthritic joint in the C57Bl/6 mouse at day 35 post immunization showing erosion of bone 
(arrows). The dotted line indicates the typical anatomy of the normal non-inflamed joint for compari-
son. C,D,E) Catecholaminergic tyrosine hydroxylase (TH) - positive nerve fibers (arrow) in a joint (C) 
and surrounding blood vessels in the skin of mouse limbs (D,E). F,G) Cholinergic vesicular acetylcho-
line transporter (VAChT) - positive nerve fibers (arrows) in muscle (F) and skin (G) of an arthritic 
mouse paw. (Stangl et al., 2015). 
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Figure 8. Density of catecholaminergic and cholinergic nerve fibers in inflamed paws of 
mice during collagen type II – induced arthritis (CIA). A) Density of catecholaminergic TH-positive 
nerve fibers. B) Density of cholinergic VAChT-positive nerve fibers. C) Ratio of cholinergic to catechol-
aminergic nerve fibers, calculated for each paw. A total of n=45 whole paws obtained from mice during 
CIA were collected at different time points post immunization. A,B,C) Each dot represents the nerve 
fiber density of one paw. Box plots demonstrate the 10th (whisker), 25th, 50th (median), 75th, 90th 
(whisker) percentile. D) Evaluation of inflamed paws: Spearman correlation of the mean clinical arthri-
tis score and the mean histological arthritis score. One dot indicates the mean clinical score and mean 
histological score at a given day post immunization. Abbreviations see previous legends. (Stangl et al., 
2015). 
 
Compared to paws from healthy mice with a density of about four sympathetic TH+ nerve fibers per 
square millimeter, the density of sympathetic TH+ nerve fibers in arthritic paws obtained on day 35 
post immunization (p.i.) significantly decreased to a value below one nerve fiber per square millimeter 
(Figure 8A). Paws from day 35 p.i. also showed significantly decreased density of sympathetic TH+ 
nerve fibers compared to paws from day 21, 25 and 28 p.i. (Figure 8A). The density of TH+ nerve 
fibers however significantly increased again towards later stages of the disease (day 55 p.i., Figure 
8A). During the course of arthritis, the density of cholinergic, VAChT+ nerve fibers in arthritic paws 
significantly increased on day 35 p.i. compared to day 21 and 25 when nearly no VAChT+ nerve fibers 
were detected (Figure 8B). The resulting ratios of densities of cholinergic VAChT+ nerve fibers divided 
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by the respective densities of sympathetic TH+ nerve fibers increased on day 35 p.i. when compared 
to ratios from control paws, day 25 and day 28 p.i. (Figure 8C). The ratio however decreased again to 
control level on day 55 p.i. (Figure 8C). The overall mean histological score which includes bone ero-
sion, tissue inflammation and cell infiltration positively correlated with the mean clinical score (Figure 
8D). 
Cholinergic, VAChT+ nerve fibers were significantly more often found in less inflamed regions in the 
paw like in muscle or skin tissue compared to highly inflamed regions like in synovium or near focal 
bony erosions (Figure 9). 
 
Figure 9. Localization of cholinergic nerve fibers in paws from arthritic C57Bl/6 mice. Each 
dot represents the nerve fiber density in one paw. Box plots demonstrate the 10th (whisker), 25th, 50th 
(median), 75th, 90th (whisker) percentile. Abbreviations: VAChT, vesicular acetylcholine transporter. 
(Stangl et al., 2015). 
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3.2 Density of sympathetic TH-positive, cholinergic VAChT-
positive and VIP-positive nerve fibers in osteoarthritis and 
rheumatoid arthritis 
3.2.1 Innervation of finger joints 
Cholinergic, VAChT+ and cholinergic VIP+ nerve fibers were detected in tissue samples obtained from 
OA and RA patients receiving finger arthrodesis surgery. The tissue samples were categorized into two 
basic groups: Samples mainly containing synovial and/or other types of connective tissue devoid of 
bone or cartilage and samples mainly containing articular bone and cartilage. Generally, VAChT+ and 
VIP+ nerve fibers were detected in both types of samples. In samples with connective tissue, VAChT+ 
nerve fibers (Figure 10A) were significantly more prevalent in samples obtained from OA patients 
compared to samples from RA patients (Figure 10B). No significant difference in the density of VIP+ 
nerve fibers (Figure 10C) was detected in connective tissue from finger joints from OA and RA pa-
tients (Figure 10D). 
 
Figure 10. Cholinergic nerve fibers in connective tissue from OA and RA finger joints. A,C) 
Examples of cholinergic VAChT-positive nerve fibers (A, arrows) and cholinergic VIP-positive nerve 
fibers (C, arrows) in connective tissue from patients with arthritic finger joints receiving arthrodesis 
surgery. Magnification x400. Autofluorescence is displayed in green, stained nerve fibers are displayed 
in red. B,D) Comparison of cholinergic VAChT-positive (B) and cholinergic VIP-positive (D) nerve fi-
bers in connective tissue from OA patients and patients with rheumatoid arthritis (RA). Each dot repre-
sents the nerve fiber density in the connective tissue of one finger joint of OA and RA patients (D,E). 
Box plots demonstrate the 10th (whisker), 25th, 50th (median), 75th, 90th (whisker) percentile.  Abbre-
viations: OA, osteoarthritis; VAChT, vesicular acetylcholine transporter; VIP, vasoactive intestinal pep-
tide; n.s., not significant. (Stangl et al., 2015). 
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In samples primarily consisting of bone and cartilage, severity of cartilage damage and bone erosion 
was evaluated by the use of DMMB staining (for explanation, see 2.4). Cartilage in healthy condition 
with a high relative content of glycosaminoglycans is stained in a deep purple color (Figure 11A). The 
amount of glycosaminoglycans in the cartilage correlates with the color intensity of DMMB staining. In 
general, inflamed synovial tissue (Figure 11B), degradation of cartilage (Figure 11B,C,D), cells invad-
ing the joint space (Figure 11C), erosions of bone (Figure 11B,D) and pannus like structures (Figure 
11D) were detected. Cholinergic VAChT+ and cholinergic VIP+ nerve fibers in bone containing tissue 
were detected (Figure 11E,G), but densities of these fibers (Figure 11F,H) were much lower than in 
connective tissue (Figure 10B,D). In contrast to finger joint samples containing connective tissue, no 
significant difference in VAChT+ nerve fiber density between bone samples obtained from OA patients 
compared to bone containing samples from RA patients was detected (Figure 11F). Similarly, no dif-
ference in VIP+ nerve fibers was observed (Figure 11H). 
 
Figure 11. Cholinergic nerve fibers in bone tissue from finger joints in OA and RA patients. 
A,B,C,D) Representative DMMB (A,B) and HE (C,D) stainings of tissue from finger joints in OA and RA 
patients. A) Unharmed part of a joint. B,C) Connective tissue invading the joint space (arrow heads) 
and spots of bone erosion (B, arrows). Loss and change of cartilage (C, arrows). D) Pannus-like struc-
ture of connective tissue (arrow heads) invading bone tissue. E) Cholinergic VAChT-positive nerve 
fibers (arrows) adjacent to blood vessels in trabecular bone. G) Cholinergic VIP-positive nerve fiber 
(arrow) in subchondral bone. Autofluorescence displayed in green, cell nuclei in blue. F,H) Compari-
son of cholinergic VAChT-positive (F) and cholinergic VIP-positive (H) nerve fibers in bone tissue from 
OA and RA patient. Numbers in parentheses indicate total number of finger joints analyzed. Abbrevia-
tions: DMMB, 1,9-dimethyl-methylene blue; HE, hematoxylin-eosin. For explanation of other abbrevia-
tions and box plots see previous figures. (Stangl et al., 2015). 
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Similarly, TH+ sympathetic nerve fibers were detected in OA and RA samples, but density of these 
nerve fibers did not differ between OA and RA samples neither in connective tissue containing material 
nor in mainly bone containing tissue (Figure 12). 
 
Figure 12. Sympathetic catecholaminergic nerve fibers in finger joint tissue from OA and RA 
patients. A,B) Examples of sympathetic TH-positive nerve fibers (A,B arrows) in samples from pa-
tients with OA receiving finger joint arthrodesis surgery. C,D) Examples of sympathetic TH-positive 
nerve fibers (C,D arrows) in samples from patients with RA receiving finger joint arthrodesis surgery. 
A,B,C,D) Magnification x400. Autofluorescence is displayed in green, TH+ stained nerve fibers are 
displayed in red. Comparison of the density of TH+ nerve fibers in samples devoid of bone tissue (E) 
and in bone tissue (F). Each dot represents the nerve fiber density in the tissue of one finger joint of 
OA and RA patients (D,E). Box plots demonstrate the 10th (whisker), 25th, 50th (median), 75th, 90th 
(whisker) percentile. Abbreviations: OA, osteoarthritis; RA, rheumatoid arthritis; TH, tyrosine hydrox-
ylase; n.s., not significant. 
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3.2.2 Innervation of knee synovial tissue of OA and RA patients 
In synovial tissue which was obtained from OA and RA patients undergoing total knee replacement 
surgery, VAChT+ (Figure 13A) and VIP+ (Figure 13C) nerve fibers with their typical bead like struc-
ture were detected. The densities of both, VAChT+ and VIP+ did not statistically differ. (Figure 13B,D). 
Density of TH+ nerve fibers in knee synovial tissue from OA and RA patients was not investigated 
since this has already been done in earlier studies. 
 
Figure 13. Cholinergic nerve fibers in synovial tissue from OA and RA patients. A,C) Exam-
ples of cholinergic VAChT-positive nerve fibers (A, arrows in upper and lower image) and cholinergic 
VIP-positive nerve fibers (C, arrows in upper and lower image) in synovial tissue from patients with 
osteoarthritis (OA) or rheumatoid arthritis (RA) undergoing total knee joint replacement surgery. Mag-
nification x400. B) Comparison of cholinergic VAChT-positive nerve fibers in synovial tissue in the 
knee from OA patients and patients with RA. D) Comparison of cholinergic VIP-positive nerve fibers in 
synovial tissue in the knee from OA patients and patients with RA. One dot indicates the mean nerve 
fiber density in the synovial tissue of one patient. Box plots demonstrate the 10th (whisker), 25th, 50th 
(median), 75th, 90th (whisker) percentile. Abbreviations: VAChT, vesicular acetylcholine transporter; 
VIP, vasoactive intestinal peptide; n.s., not significant. (Stangl et al., 2015). 
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3.2.3 Expression of the alpha-7 subtype-containing nicotinic acetyl-
choline receptor in fibroblast like synoviocytes 
In a brief test, fibroblast-like synoviocytes (FLS) from OA patients (passage 2-4) were stained for the 
alpha-7 subtype-containing nicotinic acetylcholine receptor (α7nAChR). The α7nAChR stained cells 
exhibited a positive staining (Figure 14A) compared to immunoglobulin control (Figure 14B). 
 
Figure 14. Expression of the alpha-7 subunit-containing nicotinic acetylcholine receptor 
(α7nAChR) in OA fibroblast-like synoviocytes. Example of fibroblast-like synoviocytes obtained 
from the synovial tissue of one OA patient undergoing knee replacement surgery. A) DAB staining of 
the α7nAChR in OA fibroblast-like synoviocytes. B) DAB staining of immunoglobulin control antibody. 
A,B) Magnification x200. Abbreviations: OA, osteoarthritis; DAB, 3,3'-diaminobenzidine. 
 
3.3 Induction of the cholinergic phenotype of nerve fibers in 
mice sympathetic ganglia 
To test a possible influence of different types of cells, namely draining lymph node cells and OCP cells 
from healthy and arthritic mice, on the frequency of VAChT-positive cholinergic nerve fibers in sympa-
thetic mouse ganglia, the co-culture system shown in chapter 2.6 was used. In a second approach, 
candidate molecules, which were supposedly produced by OCPs, were tested. 
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3.3.1 Co-culture experiments 
In many co-culture experiments, draining lymph node cells and OCP cells were migrating into the oth-
er half of the well after the insert was removed from the well. Nerve fibers from sympathetic ganglia 
and OCPs sometimes also came into direct contact (Figure 15). In some cases nerve fibers also 
formed basket shaped structures around these cells. 
 
Figure 15. Chemotaxis and appearance of cholinergic nerve fibers in co-culture experiments 
with osteoclast progenitor cells and sympathetic ganglia. A,B) Examples of osteoclast progenitor 
cells migrating towards the radial nerve fiber outgrowth of sympathetic ganglia. The dotted lines indi-
cate the border of the co-culture system when the silicone culture insert was still present. C,D) Sympa-
thetic nerve fibers form basket like structures around osteoclast progenitor cells, in some cases the 
nerve fibers are VAChT positive (arrows).The culture medium contained nerve growth factor, macro-
phage colony-stimulating factor, and receptor activator of nuclear factor kappa-B ligand (RANKL). 
Coculture period lasted for two days. Catecholaminergic TH-positive fibers are displayed in green, 
cholinergic VAChT-positive fibers are stained in red, and osteoclast progenitor cells in blue. A,B) Mag-
nification x50. C) Magnification x100. D) Magnification x200. Abbreviations see previous legends. 
(Stangl et al., 2015). 
 
In experiments with sympathetic ganglia from newborn C57Bl/6 mice in co-culture with draining lymph 
node cells from healthy and arthritic C57Bl/6 mice, no significant difference in the ratio of cholinergic to 
catecholaminergic nerve fibers was observed (Figure 16A). However, when OCP cells were used in 
the co-culture system, this ratio significantly increased to a mean value of above 0.5 in the case where 
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OCPs were obtained from healthy C57Bl/6 mice as compared to the same experiment with OCP cells 
from arthritic mice (Figure 16A). To check a possible strain specificity, the experiment setting was 
repeated only that draining lymph node cells and OCPs were now obtained from healthy and arthritic 
DBA1/J mice. Here, experiments with OCPs from healthy DBA1/J mice again resulted in higher ratios 
as compared to co-cultures with cells from mice with CIA (Figure 16B). In addition, in contrast to ex-
periments in which both cell types were gathered from C57Bl/6 mice, assays with draining lymph node 
cells from healthy DBA1/J mice displayed significantly higher ratios compared to experiments with 
cells from arthritic mice (Figure 16B). 
 
Figure 16. Ratio of cholinergic to catecholaminergic nerve fibers from sympathetic ganglia 
of newborn C57Bl/6 mice in co-culture experiments with osteoclast progenitor cells and drain-
ing lymph node cells from healthy and arthritic adult C57Bl/6 animals (A) or DBA1/J mice (B). 
The control situation reflects sympathetic ganglia only without osteoclast progenitor cells or draining 
lymph node cells. Each dot indicates the ratio of red pixel positivity for cholinergic VAChT-positive 
nerve fibers divided by green pixel positivity of sympathetic TH-positive nerve fibers of one digitally 
analyzed image. Numbers in parentheses indicate total number of sympathetic ganglia analyzed. Box 
plots demonstrate the 10th (whisker), 25th, 50th (median), 75th, 90th (whisker) percentile. Abbrevia-
tions: Co, control; CIA, collagen type II-induced arthritis; VAChT, vesicular acetylcholine transporter; 
TH, tyrosine hydroxylase. (Stangl et al., 2015). 
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3.3.2 Stimulation of sympathetic ganglia 
After the genome and proteome of the OCP cells from healthy and arthritic mice was analyzed (see 
3.4 and 3.5) several candidate molecules were selected as possible soluble transition factors respon-
sible for the increased frequency of VAChT+ cholinergic nerve fibers in sympathetic ganglia. First, LIF, 
which is a known transition factor for sympathetic nerve fibers, was identified as a possible molecule 
released by OCPs (see 3.4 and 3.5) and tested in the assay with sympathetic ganglia. Stimulation of 
sympathetic ganglia with 100ng/mL of LIF significantly increased the ratio of VAChT+ cholinergic to 
TH+ catecholaminergic nerve fibers (Figure 17). This effect was augmented if the stimulation with LIF 
was performed in culture medium containing progesterone since stimulations with LIF but without pro-
gesterone showed significantly lower ratios of VAChT+ to TH+ nerve fibers (Figure 17). 
 
Figure 17. Stimulation of sympathetic ganglia with leukemia inhibitory factor (LIF) under dif-
ferent conditions. The effect of LIF on the ratio of VAChT+ cholinergic to TH+ catecholaminergic 
nerve fibers in sympathetic ganglia was tested with different concentrations of NGF. Additionally the 
effect of progesterone in the culture medium was tested. Sympathetic ganglia were grown for 2 d with 
or without progesterone with 100ng/mL of NGF and after 2 d received fresh culture medium with a 
lower concentration of NGF with or without progesterone and with or without LIF. After 2 d, ganglia 
were fixed, subjected to double immunofluorescence staining and subsequently digitally analyzed. 
Each dot indicates the ratio of red pixel positivity for cholinergic VAChT-positive nerve fibers divided by 
green pixel positivity of sympathetic TH-positive nerve fibers of one digitally analyzed image. Numbers 
in parentheses indicate total number of sympathetic ganglia analyzed. Box plots demonstrate the 10th 
(whisker), 25th, 50th (median), 75th, 90th (whisker) percentile. Abbreviations: NGF, nerve growth fac-
tor; other abbreviations see previous legends. (Stangl et al., 2015). 
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In addition to experiments with LIF, further stimulation assays of sympathetic ganglia with TIMP-1 and 
BGN (biglycan) were conducted due to the fact that these two molecules showed enhanced expres-
sion in the gene expression analysis (see 3.4) and, in the case of TIMP-1, also in the proteome analy-
sis of OCP cells. Stimulations with biglycan and TIMP-1 significantly enhanced the ratio of VAChT-
positive to TH-positive nerve fibers in sympathetic ganglia (Figure 18) but not as strong as LIF (Figure 
17) or in co-culture with OCP cells in (Figure 16A). 
 
Figure 18. Stimulation of sympathetic ganglia with biglycan (BGN) or tissue inhibitor of met-
alloproteinase 1 (TIMP-1). The effect of BGN and TIMP-1 on the ratio of VAChT+ cholinergic to TH+ 
catecholaminergic nerve fibers in sympathetic ganglia was tested. Sympathetic ganglia were grown for 
2 d with progesterone and 100ng/mL of NGF and after 2 d received fresh culture medium with 
25ng/mL of NGF with progesterone and with BGN or TIMP-1, respectively. After 2 d, ganglia were 
fixed, subjected to double immunofluorescence staining and subsequently digitally analyzed. Each dot 
indicates the ratio of red pixel positivity for cholinergic VAChT-positive nerve fibers divided by green 
pixel positivity of sympathetic TH-positive nerve fibers of one digitally analyzed image. Numbers in 
parentheses indicate total number of sympathetic ganglia analyzed. Box plots demonstrate the 10th 
(whisker), 25th, 50th (median), 75th, 90th (whisker) percentile. Abbreviations: BGN, biglycan; TIMP-1, 
tissue inhibitor of metalloproteinase 1; other abbreviations see previous legends. 
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In contrast to the control situation with only poly-D-lysine coated chambers, coating with fibronectin 
and stimulation with RGDS tetra-peptide resulted in a very dense and overlapping, bundle-like out-
growth of sympathetic nerve fibers (Figure 19B,C). Due to this dense, overlapping outgrowth of nerve 
fibers, double immunofluorescence detection of VAChT+ and TH+ nerve fibers resulted in staining 
which was not suitable for quantification of VAChT and TH pixel positivity and respective results were 
regarded as not applicable for interpretation. Still, the observed effects of fibronectin and RGDS on the 
morphology of sympathetic nerve fiber outgrowth are noteworthy (Figure 19). 
 
Figure 19. Effects of Fibronectin and RGDS on the outgrowth of nerve fibers from sympa-
thetic ganglia. A) Control situation with standard poly-D-lysine coated chamber surface displays typi-
cal radial outgrowth of nerve fibers with nerve fibers showing individual and separate sprouting (image 
is color-inverted for better contrast). B) Stimulation of sympathetic ganglia with RGDS peptide leads to 
a more dense, overlapping and bundle like outgrowth of nerve fibers. C) Incidence of inhibited nerve 
fiber outgrowth and very intense clustered nerve fibers surrounding the ganglion soma is increased in 
fibronectin coated and RGDS stimulated ganglia. Abbreviations: RGDS, arginin-glycin-aspartate-serin 
tetrapeptide. Brightfield, magnification x50. 
 
3.4 Gene expression levels of osteoclast progenitor cells 
Based on the results from the co-culture experiments with OCP cells differentiated for 2 d which re-
sulted in an enhanced frequency of cholinergic nerve fibers in sympathetic ganglia, the transcriptome 
of OCPs obtained from healthy control and arthritic mice was investigated. The results of cells differen-
tiated for 2 d are highlighted on the left side of the table, while the gene expression values of cells 
differentiated for 5 d are for comparison displayed on the right part of the table (Figure 20) (Stangl et 
al., 2015). 
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Figure 20. Results from microarray gene expression analysis of osteoclast progenitors 
(OCP) from healthy and arthritic mice. Whole RNA was isolated from OCPs obtained from arthritic 
(n=3) and age corresponding healthy control animals (n=3) (left table). OCPs were differentiated for 2 
d with M-CSF and RANKL (left table). Negative values (bright background) in mean fold change indi-
cate higher mRNA expression of the respective genes in cells obtained from healthy animals while 
positive values (dark background) indicate higher expression in cells from arthritic mice. For compari-
son, gene expression was also analyzed from OCPs obtained from arthritic (n=2) and corresponding 
healthy controls (n=2) which were differentiated for 5 d with M-CSF and RANKL (right table, white 
background). Isolated whole RNA was analyzed with the Affymetrix GeneChip mouse Gene 2.0 ST 
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array. Abbreviations: M-CSF, macrophage colony stimulating factor; RANKL, receptor activator of nu-
clear factor-kappa-B ligand. (Stangl et al., 2015). 
 
3.4.1 Gene expression in osteoclast progenitor cells from healthy mice 
The gene expression values are given in mean fold changes, with signals from RNA obtained from 
arthritic mice being compared to signals from RNA obtained from healthy mice as control. This has the 
consequence that positive values in the mean fold change indicate an up-regulation of a given gene in 
cells from arthritic mice, while negative values indicate a relative up-regulation in cells from healthy 
control animals. Following transcripts were up-regulated in for 2 d differentiated OCP cells from 
healthy mice compared to cells from arthritic animals with an assumed threshold value for up-/down-
regulation of approximately +/-2.0: Biglycan (-5.19), tenascin C (-4.09), tetraspanin 7 (-3.44), tissue 
inhibitor of metalloproteinase 1 (-3.41), osteoclast associated receptor (-2.83), fibronectin 1 (-2.75), 
tensin 1 (-2.73), periostin (-2.57), connective tissue growth factor (-2.48), leukemia inhibitory factor (-
2.40), dendrocyte expressed seven transmembrane protein (-2.29), osteoclast stimulatory transmem-
brane protein (-2.10), secreted acidic cysteine rich glycoprotein (-1.98) (Figure 20). In cells differenti-
ated for 5 d, transcripts for Biglycan (-3.01) and tissue inhibitor of metalloproteinase 1 (-2.49) were still 
significantly up-regulated in cells from healthy mice, while a trend towards higher expression was ob-
servable for fibronectin 1 (-2.60) and secreted acidic cysteine rich glycoprotein (-2.27) (Figure 20). 
3.4.2 Gene expression in osteoclast progenitor cells from arthritic 
mice 
In contrast, following transcripts of genes were significantly and markedly up-regulated in OCPs from 
arthritic mice: Ccl8 (+3.28), Il1a (+3.53), Ccr5 (+3.63), Cxcl3 (+3.67), Ccl5 (+4.09), Tnf (+4.14), Ccl12 
(+5.06), Ccl4 (+5.42), Il1b (+6.07), Ccl3 (+6.37), Ccl6 (+8.20), Mmp8 (+9.61), Cxcl2 (+10.21), Ccl2 
(+11.18), Marco (+13.24), Ccl7 (+18.31) and Saa3 (+52.86) (for details and abbreviations see Figure 
20). However, none of these gene transcripts was up-regulated in cells differentiated for 5 consecutive 
days (Figure 20). 
3.4.3 Clustering of selected genes in osteoclast progenitor cells 
In order to visualize the results given in Figure 20, a clustering algorithm was used to group subsets 
of genes resulting in a color coded image which indicates how strong the relation of expression signals 
of the respective genes to each other is (Figure 21). 
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Figure 21. Clustered and color-coded heat map with clustering trees describing gene ex-
pression signal intensities from microarray analysis of osteoclast progenitor cells. A) Only the 
columns (=samples, control n=3, CIA n=3) are clustered; The given genes (1-30) are ordered after the 
mean fold change value of the respective gene (see previous figure). B) Columns (=samples) and 
rows (=genes) are clustered; Branching of the clustering tree indicates groups of genes with similar 
gene expression levels. A,B) Used clustering settings were Euclidean distance method and average 
linkage cluster algorithm. Abbreviations: see previous figure legends. 
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3.5 Proteome analysis of osteoclast progenitor cells 
In the next step, cell culture supernatants of OCP cells obtained from healthy and arthritic mice were 
generated to check whether the observed changes in the gene expression also translated into chang-
es of the respective protein concentrations. A general, relative expression screening with the help of 
the proteome profiler method was conducted, followed by quantitative ELISA measurements of single 
proteins. 
3.5.1 Proteome profiler results 
From the n=10 supernatants generated by OCP cells from healthy mice, n=4 were selected and sub-
jected to the proteome profiler assay. Analogically, n=4 supernatants were picked from n=10 samples 
generated by OCPs from arthritic mice. A total of 40 proteins was screened with this technique. The 
results are displayed in two separate charts. In general, most of the cytokines investigated displayed a 
higher expression in supernatants harvested from OCP cells obtained from arthritic mice. In particular, 
interferon gamma (IFNγ), interleukins 1 alpha and beta, interleukins 3, 4, 6, 7, 10, 13, 16, 17, 23, 27, 
TREM-1 (all Figure 22), and chemokine (C-C motif) ligands 1, 2, 3, 5, and chemokine (C-X-C motif) 
ligands 9, 10, 11, 12, 13 showed stronger expressions (Figure 23).  
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Figure 22. Cytokine profile (I) in supernatants of osteoclast progenitor cells. Proteome profil-
er mouse cytokine array panel A membranes were used for analysis of a total of 40 cytokines (see 
also figure 16). One dot or triangle indicates the relative signal intensity of one cytokine in the super-
natant generated by cells from one animal. Black dots and white box plots indicate supernatants ana-
lyzed from control animals (n=4), whereas white triangles and red box plots indicate supernatants 
analyzed from arthritic animals (n=4). Box plots demonstrate the 10th (whisker), 25th, 50th (median), 
75th, 90th (whisker) percentile. Abbreviations: IFNy, interferon gamma; IL, interleukin; IL-1a, interleu-
kin 1alpha; IL-1b, interleukin 1beta; IL-1ra, interleukin 1 receptor antagonist; TIMP-1, tissue inhibitor of 
metalloproteinase 1; TNF, tumor necrosis factor; TREM-1, triggering receptor expressed on myeloid 
cells 1; n.s., not significant. 
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Figure 23. Cytokine profile (II) in supernatants of osteoclast progenitor cells. Proteome profil-
er mouse cytokine array panel A membranes were used for analysis of a total of 40 cytokines (see 
also previous figure 15). One dot or triangle indicates the relative signal intensity of one cytokine in the 
supernatant generated by cells from one animal. Black dots and white box plots indicate supernatants 
analyzed from control animals (n=4), whereas white triangles and red box plots indicate supernatants 
analyzed from arthritic animals (n=4). Box plots demonstrate the 10th (whisker), 25th, 50th (median), 
75th, 90th (whisker) percentile. Abbreviations: CCL, chemokine (C-C motif) ligand; CXCL, chemokine 
(C-X-C motif) ligand; C5a, complement component 5a, in mouse known as Hc, hemolytic complement; 
Gcsf, colony stimulating factor 3 (granulocyte); Icam1, intercellular adhesion molecule 1; Mcsf, colony 
stimulating factor 1 (macrophage); n.s., not significant. 
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3.5.2 ELISA results of supernatants from osteoclast progenitor cells 
3.5.2.1 Oncostatin M (OSM) and tissue inhibitor of metalloproteinase 1 
(TIMP-1) 
Oncostatin M (OSM) was detectable at very low concentrations in both kinds of supernatants (healthy 
and arthritic). Levels of OSM in samples of cells gathered from control mice were significantly higher 
than respective samples from arthritic mice (Figure 24A). TIMP-1 was detectable in both, control and 
CIA supernatants. Samples from cells obtained from healthy animals displayed significantly higher 
concentrations than samples from arthritic animals (Figure 24B), which confirms gene expression 
studies. 
 
Figure 24. Levels of oncostatin M (OSM) and tissue inhibitor of metalloproteinase 1 (TIMP-1) 
in cell culture supernatants of osteoclast progenitor cells. One dot indicates the mean level of 
protein generated by cells from one animal. Numbers in parentheses indicate total number of samples 
analyzed. Box plots demonstrate the 10th (whisker), 25th, 50th (median), 75th, 90th (whisker) percen-
tile. Abbreviations: OSM, oncostatin M; TIMP-1, tissue inhibitor of metalloproteinase 1; CIA, collagen 
type II-induced arthritis; A,B) The dotted line indicates the lowest standard used in the ELISA. (Stangl 
et al., 2015). 
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3.5.2.2 LIF in cell culture supernatants of osteoclast progenitor cells 
LIF was detectable in cell culture supernatants from OCP cells obtained from healthy control and ar-
thritic mice. The amount of LIF did not significantly differ between the two groups (Figure 25). Due to 
the relevance of LIF as a potential transition factor of sympathetic nerve fibers, also cell lysates of 
BMM were measured. LIF was hardly detectable in these samples (Figure 25). 
 
Figure 25. Levels of LIF in cell culture supernatants and cell lysates from osteoclast progen-
itor cells. One dot indicates the mean level per sample. Lower detection limit (~3 pg/mL) indicated by 
dashed line. Numbers in parentheses indicate number of samples analyzed. Box plots demonstrate 
the 10th (whisker), 25th, 50th (median), 75th, 90th (whisker) percentile. Abbreviations: LIF, leukemia 
inhibitory factor; CIA, collagen induced arthritis; n.s., not significant. (Stangl et al., 2015). 
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3.5.2.3 Progesterone in cell culture supernatants of osteoclast progenitors 
and in synovial fluid of OA and RA patients 
Since possible binding sites for steroids were detected within the cholinergic gene locus (see 3.6), 
supernatants of OCPs and synovial fluid of OA and RA patients were tested for progesterone. Proges-
terone was detectable in low concentrations (sensitivity 0.045ng/mL) in cell culture supernatants from 
OCP cells and in synovial fluid obtained from OA and RA patients. No significant difference was ob-
served between control and arthritic samples or OA and RA samples respectively (Figure 26A,B). 
 
Figure 26. Levels of progesterone in cell culture supernatants of osteoclast progenitor cells 
(A) and synovial fluid of OA and RA patients (B). One dot indicates the mean level of protein per 
sample. Numbers in parentheses indicate total number of samples analyzed. Box plots demonstrate 
the 10th (whisker), 25th, 50th (median), 75th, 90th (whisker) percentile. Lowest standard used in the 
ELISA is 0.30 ng/mL and sensitivity is 0.045ng/mL according to the manufacturer‘s instructions. Ab-
breviations: OA, osteoarthritis; RA, rheumatoid arthritis; CIA, collagen type II-induced arthritis; n.s., not 
significant. 
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3.5.2.4 MCP-1 (CCL2) and MCP-3 (CCL7) 
Since gene expression analysis showed enhanced expression of MCP-1 (CCL2) and MCP-3 (CCL7) 
transcripts in OCPs from arthritic mice, respective supernatants were tested for these proteins. Indeed, 
the two monocyte chemoattractant proteins MCP-1 (CCL2) and MCP-3 (CCL7) were detected in cell 
culture supernatants of both, healthy and arthritic cell cultures in high concentrations. Samples had to 
be diluted to reach the respective range of the ELISA. However, the measured concentrations did not 
significantly differ between control and CIA samples (Figure 27A,B). 
 
Figure 27. Levels of CCL2/MCP-1 (A) and CCL7/MCP-3 (B) in cell culture supernatants of os-
teoclast progenitor cells. One dot indicates the mean level of protein generated by cells from one 
animal. Numbers in parentheses indicate total number of samples analyzed. Box plots demonstrate 
the 10th (whisker), 25th, 50th (median), 75th, 90th (whisker) percentile. Abbreviations: CCL2, chemo-
kine (C-C motif) ligand 2; MCP-1, monocyte chemoattractant protein-1; CCL7, chemokine (C-C motif) 
ligand 7; MCP-3, monocyte chemoattractant protein-3; CIA, collagen type II-induced arthritis; n.s., not 
significant. A,B) The dotted line indicates the lowest standard used in the ELISA. 
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3.5.2.5 CCL3/MIP-1a and CXCL2/MIP-2a 
Since gene expression analysis showed enhanced expression of MIP-1a (CCL3) and MIP-2a (CXCL2) 
transcripts in OCPs from arthritic mice, respective supernatants were tested for these proteins. The 
two macrophage inflammatory proteins MIP-1a (CCL3) and MIP-2a (CXCL2) were both detected in 
cell culture supernatants from OCP cells. However, there was no significant difference between control 
and CIA samples (Figure 28A,B). 
 
Figure 28. Levels of CCL3/MIP-1a (A) and CXCL2/MIP-2a (B) in cell culture supernatants of 
osteoclast progenitor cells. One dot indicates the mean level of protein generated by cells from one 
animal. Numbers in parentheses indicate total number of samples analyzed. Box plots demonstrate 
the 10th (whisker), 25th, 50th (median), 75th, 90th (whisker) percentile. Abbreviations: CCL3, chemo-
kine (C-C motif) ligand 3; MIP-1a, macrophage inflammatory protein-1a; CXCL2, chemokine (C-X-C 
motif) ligand 2; MIP-2a, macrophage inflammatory protein-2a; CIA, collagen type II-induced arthritis; 
n.s., not significant. A,B) The dotted line indicates the lowest standard used in the ELISA. 
  
3.5 Proteome analysis of osteoclast progenitor cells 
59 
 
3.5.2.6 CCL5/RANTES and CXCL10 
Since gene expression and proteome analysis showed enhanced expression of RANTES (CCL5) and 
CXCL10 in OCPs from arthritic mice, respective supernatants were tested for these proteins with 
ELISA. The proteins CCL5/RANTES and CXCL10 were both detected in cell culture supernatants 
from OCP cells in control and CIA samples. Comparing the median values, concentrations of CCL5 in 
samples obtained from arthritic mice were significantly higher (p=0.002) than concentrations in control 
samples (Figure 29A). There was no significant difference in the amount of CXCL10 in control and 
CIA samples (Figure 29B). 
 
Figure 29. Levels of CCL5/RANTES (A) and CXCL10 (B) in cell culture supernatants of oste-
oclast progenitor cells. One dot indicates the mean level of protein generated by cells from one ani-
mal. Numbers in parentheses indicate total number of samples analyzed. Box plots demonstrate the 
10th (whisker), 25th, 50th (median), 75th, 90th (whisker) percentile. Abbreviations: CCL5, chemokine 
(C-C motif) ligand 5; RANTES, regulated upon activation, normally T-cell expressed and presumably 
secreted; CXCL10, chemokine (C-X-C motif) ligand 10; CIA, collagen type II-induced arthritis; n.s., not 
significant. A,B) The dotted line indicates the lowest standard used in the ELISA. 
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3.5.2.7 Periostin/OSF2 and CXCL12/SDF-1 
Since gene expression and proteome analysis suggested different expressions of Periostin/OSF2 and 
CXCL12/SDF-1 in OCPs obtained from arthritic and healthy control mice, supernatants of these cells 
were tested for these proteins with the help of specific ELISA. Although some samples produced ex-
tremely weak signals in the periostin and CXCL12 ELISA, both proteins were regarded as not detect-
able in cell culture supernatants from OCPs since the signals were far below the lowest standards 
which were used in the respective ELISA (Figure 30). 
 
Figure 30. Levels of Periostin/OSF-2 (A) and CXCL12/SDF-1 (B) in cell culture supernatants 
of osteoclast progenitor cells. One dot indicates the mean level of protein generated by cells from 
one animal. Numbers in parentheses indicate total number of samples analyzed. Box plots demon-
strate the 10th (whisker), 25th, 50th (median), 75th, 90th (whisker) percentile. Abbreviations: OSF-2, 
osteoblast specific factor; CXCL12, chemokine (C-X-C motif) ligand 12; SDF-1, stromal cell-derived 
factor 1; CIA, collagen type II-induced arthritis; A,B) The dotted line indicates the lowest standard used 
in the ELISA. 
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3.6 Analysis of promoter regions in the cholinergic gene locus 
in the murine and human genome 
Binding elements for steroids within promoter regions of both VAChT (vesicular acetylcholine trans-
porter) genes SLC18A3 (human) and slc18a3 (mouse), which are part of the cholinergic gene locus, 
were detected. 
3.6.1 Detection of steroid binding sites in the promoter region of the 
murine vesicular acetylcholine transporter gene 
In the mouse gene of VAChT (slc18a3) the base sequence ctgcctccatcTGTTctcg (bases in capital 
represent the four highest conserved bases of the respective matrix) was identified as a V$PRE.01 
(progesterone receptor binding site) matrix belonging to the family of V$GREF (glucocorticoid respon-
sive and related elements) matrices. This sequence was positioned on the minus strand at bases 39 – 
57 with an anchor at base 48 out of a total of 601 bases representing the whole VAChT sequence. The 
matrix similarity, in which the algorithm of the software estimates matches and mismatches comparing 
the investigated sequence with the conserved sequence of the specific matrix, was rated with 0.888 
out of a maximum of 1.0. The software algorithm sets an internal threshold for calculated results to 
0.80, discarding any results below this value (Cartharius et al., 2005). 
3.6.2 Detection of steroid binding sites in the promoter region of the 
human vesicular acetylcholine transporter gene 
Similar to the murine gene, in the human gene of VAChT (SLC18A3), the base sequence 
ctgcgtccatcTGTTctcg (bases in capital represent the four highest conserved bases of the respective 
matrix) was identified as a V$PRE.01 (progesterone receptor binding site) matrix belonging to the 
family of V$GREF (glucocorticoid responsive and related elements) matrices. This sequence was 
positioned on the minus strand at bases 28 – 46 with an anchor at base 37 out of a total of 601 bases 
representing the whole VAChT sequence. The matrix similarity was rated with 0.890 out of a maximum 
of 1.0. Additionally, the sequence gagGGACatgctgttgccg, positioned at bases 572 – 590 on the minus 
strand with an anchor at base 581, was identified as a V$GRE.02 (glucocorticoid receptor IR3 site) 
matrix also belonging to the family of V$GREF (glucocorticoid responsive and related elements) matri-
ces. The matrix similarity was rated 0.879 out of a maximum of 1.0. 
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4 Discussion 
4.1 Catecholaminergic and cholinergic nerve fibers in mouse 
limbs during experimental arthritis 
In this chapter, the results are being discussed in respect to current literature dealing with the plasticity 
of sympathetic catecholaminergic and cholinergic nerve fibers in arthritis and other inflammatory con-
ditions. Additionally, cholinergic signaling in cells and tissues relevant to arthritis is being discussed. 
4.1.1 Plasticity of sympathetic nerve fibers in arthritis and other in-
flammatory conditions 
In this study, the experiment with collagen induced arthritis in C57Bl/6 mice showed a gradually declin-
ing density of sympathetic, tyrosine hydroxylase-positive (TH+) nerve fibers with a minimum density of 
TH+ nerve fibers at day 35 post immunization (Figure 8A). This result is in concordance with earlier 
studies and marks a surprising turning point in the course of collagen type II induced arthritis in mice, 
at which the acute phase switches to a subacute transient state and an (early) chronic stage (Pongratz 
& Straub, 2013). These disease stages are typically characterized by relatively high clinical and histo-
logical scores, identified by strong edema, swelling of paw joints, inflamed synovial membrane, ero-
sions of bone and infiltration of immune cells into the joint cavity and finally a subsequent destruction 
of the joint integrity. This loss of TH+ sympathetic catecholaminergic nerve fibers in tissues, which are 
characterized by high local inflammation like the synovial tissue in arthritic joints, is also a known phe-
nomenon in RA (Miller et al., 2000; Weidler et al., 2005) and in animal models of arthritis, which have 
been thoroughly reviewed (Pongratz & Straub, 2013; Schaible & Straub, 2014; Straub, 2012; Straub et 
al., 2013). Interestingly, the loss of sympathetic TH+ nerve fibers does not seem not to be restricted to 
highly inflamed joint tissues in arthritis but was also described in early inflamed pancreatic islands of 
BioBreeder diabetic rats (Mei et al., 2002), in the spleen and in draining lymph nodes of arthritic rats 
and mice (Lorton et al., 2005; Lorton et al., 2009; Straub et al., 2008b), chronic Charcot foot (Koeck et 
al., 2009), colorectal adenomatous polyps (Graf et al., 2012), in intratumoral arterioles in gastric can-
cer (Miyato et al., 2011), in the myocardium after myocardial infarction (Parrish et al., 2010), and in the 
colon wall of Crohn’s patients (Straub et al., 2008a). In chronic pruritus, prurigo nodularis and in in-
frapatellar fat pad from anterior knee pain patients, a relative loss of sympathetic innervation is ob-
served because sensory innervation increases while the total amount of sympathetic nerve fibers 
4.1 Catecholaminergic and cholinergic nerve fibers in mouse limbs during experimental arthritis 
63 
 
stays unchanged (Haas et al., 2010; Lehner et al., 2008). Yet, there are two studies describing an 
increase of sensory as well as sympathetic nerve fibers in the synovial membrane during the course of 
experimental arthritis in rodents (Jimenez-Andrade & Mantyh, 2012; Longo et al., 2013). The authors 
of the first report show that the sprouting of sympathetic nerve fibers primarily takes place in joint-
adjacent tissue like the skin as compared to sprouting of sensory nerves mainly in the synovial tissue 
(Longo et al., 2013). However, an increase of sympathetic innervation in the joint might be a unique 
feature to the mono-arthritis model the authors used, featuring direct intra-articular injection of only 
CFA (complete Freund adjuvant) without a long-term antigen-driven inflammation like with type II col-
lagen in the CIA model of arthritis or in RA in humans. Interestingly, a study in which the authors com-
pared the synovial tissue from OA patients with control tissue from healthy animals, densities of both, 
sympathetic and sensory nerve fibers in OA synovium negatively correlated with the severity of in-
flammation, indicated by evaluating the Krenn score (Eitner et al., 2013). In contrast, in fat tissue sur-
rounding the synovial membrane of RA patients, an increased density of sympathetic nerves com-
pared to OA has been reported (Straub et al., 2011). To make things even more complex, in addition to 
an observed loss of TH-positive sympathetic nerve fibers, in inflamed synovial tissue from RA patients 
cells positive for TH appear (Capellino et al., 2010; Capellino et al., 2012; Miller et al., 2000) seemingly 
to at least partially compensate for missing local supply with catecholamines (Schaible & Straub, 
2014). 
The reasons for the different changes of densities of sympathetic and sensory nerve fibers in inflam-
matory tissues are complex and seem to be driven by different mechanisms: First, nerve growth factor 
(NGF), a protein belonging to the neurotrophin familiy of growth factors, which is expressed by a varie-
ty of tissues and cell types, induces general sprouting and maintenance of sympathetic as well as 
sensory peripheral nerve fibers (Sofroniew et al., 2001). NGF was found to be highly elevated in the 
synovial tissue of affected joints in an animal model of arthritis (Aloe et al., 1993). This suggests a 
growth-promoting effect on both, sympathetic and sensory nerve fibers (Levi-Montalcini, 1952; 
Pongratz & Straub, 2013; Straub et al., 2008b). The limiting of growth and the axon guidance of sym-
pathetic nerves is tightly controlled by semaphorins, a class of proteins which, amongst various other 
functions, typically displays nerve fiber repellent characteristics (Pasterkamp, 2012). The semaphorin 
subtypes 3C and 3F were shown to be specific repellents for sympathetic but not sensory nerve fibers 
and they were shown to be increased in RA and Crohn’s patients, which locally results in a net in-
crease of sensory over sympathetic innervation in these diseases (Fassold et al., 2009; Koeck et al., 
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2009; Miller et al., 2000; Miller et al., 2004; Straub et al., 2008a). In conditions in which also sema-
phorin 3A, a nerve fiber repellent capable of repelling also sensory nerves, is elevated, consequently 
also densities of both types of nerve fibers are decreased (Graf et al., 2012). Recently, even other 
possible mechanisms for the loss of sympathetic nerve fibers have been proposed: In general, human 
and rat tyrosine hydroxylase, the key enzyme of catecholamine synthesis, can be degraded via phos-
phorylation of the residues serine 19 and 40 and subsequent proteasomal degradation by ubiquitina-
tion (Tekin et al., 2014). More specifically, ubiquitination can be triggered by the gp130 class cytokines 
LIF and CNTF via an ERK1/2 (extracellular signal-regulated kinases-1/2) dependent pathway 
(Nakashima, 2012; Shi & Habecker, 2012; Tekin et al., 2014). Additionally in rat neurons, CNTF also 
seems to inhibit Phox2a, an important transcription factor for the expression of noradrenergic markers 
TH and DBH (dopamine beta hydroxylase) (Dziennis & Habecker, 2004). 
The observed increase of TH-positive sympathetic nerve fibers towards the end of the experiment of 
this study (day 55 post immunization) (Figure 8A) might resemble a beginning reverse or healing of 
inflammatory conditions in later more chronical stages of the disease. This might, due to decreasing 
concentrations of semaphorin subtypes 3F/C and possibly gp130 class cytokines, enable sympathetic 
nerve fibers to sprout back into the now less inflamed joint regions and to express TH. 
Taken together, changes in the sympathetic innervation greatly depend on different aspects, like the 
type of disease or model of experimental arthritis, the time point of detection (acute, subacute, chron-
ic), the inflammatory status and the exact type of the investigated tissue, density and type of vascular-
ization (Haywood & Walsh, 2001), the target antigen (TH, DBH, VMAT [vesicular monoamine trans-
porter, catecholaminergic marker], SP, CGRP), and presence of expression-promoting or inhibiting 
factors (all aspects reviewed in (Schaible & Straub, 2014)). However, this study and most of the litera-
ture back the hypothesis that during highly inflammatory episodes of arthritis, sympathetic nerve fibers 
positive for TH are being lost in the highly inflamed joint regions like the synovial tissue (Schaible & 
Straub, 2014). 
4.1.2 Cholinergic nerve fibers in mouse limbs during arthritis 
The aim of this study was to investigate a possible transition of sympathetic catecholaminergic TH- 
positive nerve fibers to a cholinergic phenotype of sympathetic nerve fibers, similar to the phenomena 
observed during the innervation of sweat glands and the periosteum (Asmus et al., 2000; Asmus et al., 
2001; Landis et al., 1988; Landis, 1996), which impressively demonstrate plasticity of sympathetic 
nerve fibers. Hence, it might well be that the observed loss of sympathetic nerve fibers is due to the 
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focus of sympathetic nerve fibers via detection of TH and that sympathetic nerve fibers as such remain 
and just loose TH but show cholinergic features. 
So far, cholinergic nerve fibers in limbs have never been investigated in the aspect of experimental 
arthritis. The experiment in this study shows an increase of cholinergic VAChT-positive nerve fibers 
during the course of arthritis. Strikingly, this observation is most prominent on day 35 post immuniza-
tion (Figure 8B), marking the same time point at which the limbs display a minimum of sympathetic 
innervation (Figure 8A). On day 35 post immunization, this shifted the ratio of innervation from a pre-
dominantly sympathetic to a predominantly cholinergic innervation of the investigated limbs (Figure 
8C). Intriguingly, the density of VAChT-positive cholinergic nerve fibers in these limbs decreases to-
wards the end of the observed time period (day 55 post immunization), at which the density of sympa-
thetic nerve fibers increases (Figure 8A,B). This might, similar to the increasing amount of sympathet-
ic nerves, be due to a declining severity of inflammation towards a late state of experimental arthritis, 
which could reverse the observed changes of innervation. 
However, while sympathetic nerve fibers were found throughout the investigated limb in different kinds 
of tissues (skin, bone, synovial membrane and other connective tissues in the joint), most of all of the 
VAChT-positive, cholinergic nerve fibers occurred in joint-adjacent tissue like muscle or skin (Figure 
9), which are minimally inflamed regions of the arthritic limbs. Apart from the well documented cholin-
ergic innervation of sweat glands in rodent paws (Landis et al., 1988; Landis, 1996), VAChT-positive, 
cholinergic nerve fibers in rodent limbs were also shown in other studies: VAChT immunoreactive 
nerve fibers were detected at the motor endplate of skeletal muscles in limbs (Guidry & Landis, 2000; 
Guidry et al., 2005). Regarding VAChT-positive nerve fibers adjacent to vasculature in rodent muscles, 
which were not found in mouse experiments of this present study, there are contradictory reports 
(Guidry & Landis, 2000; Schafer et al., 1998). The few VAChT-positive cholinergic nerve fibers which 
were directly located in highly inflamed regions in the synovial tissue or near bony erosions (Figure 9) 
can be explained by the cholinergic innervation of the periosteum (Asmus et al., 2000; Asmus et al., 
2001; Bjurholm et al., 1988; Hill & Elde, 1991; Hohmann et al., 1986), the recently described VAChT-
positive cholinergic nerve fibers in trabecular bone of the femoral metaphysis from mice (Bajayo et al., 
2012), and studies reporting cholinergic VIP immunoreactivity alongside catecholaminergic sympathet-
ic markers (NPY, DBH) in the synovial tissue and bone of rats (Bjurholm et al., 1988; Bjurholm et al., 
1990; Sisask et al., 1996) (reviewed in (Eimar et al., 2013)). In addition, in a very recent study, VAChT-
positive cholinergic nerve fibers have also been found in bone defects in an osteoporosis model of the 
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rat (Lips et al., 2014). Interestingly, the sympathetic nature of cholinergic (VIP-positive) nerve fibers in 
the periosteum was proven by treatment of animals with guanethidine, a substance which is specifical-
ly toxic for sympathetic nerves (Cherruau et al., 2003; Hill & Elde, 1991). This was confirmed by oth-
ers, who demonstrated the sympathetic origin of cholinergic innervation of the periosteum by gan-
glionectomy of sympathetic ganglia (Hohmann et al., 1986). 
These studies clearly demonstrate that along sympathetic catecholaminergic innervation there also 
exists a cholinergic innervation of the bone. Yet it remains unclear why VAChT-positive nerve fibers 
seem to increase during the course of experimental arthritis in rather healthy (skin and muscle) but not 
in highly inflamed tissue such as the inflamed synovial membrane, since in synovial fluid of OA and RA 
patients the presence of gp130 class cytokines like LIF or OSM, which are capable of inducing sympa-
thetic transition, has been shown (Lotz et al., 1992; Tsuchida et al., 2014) (reviewed in (Kapoor et al., 
2011; Westacott & Sharif, 1996)). One might also argue that, even if sympathetic catecholaminergic 
nerve fibers in highly inflamed regions like the synovial tissue displayed the phenomenon of a transi-
tion to a cholinergic type of sympathetic nerves, they might still be repelled by semaphorins 3F and 
3C, which are present in inflamed synovial tissue and are specific for sympathetic nerve fibers 
(Fassold et al., 2009; Miller et al., 2004). Another possible reason could be that sympathetic nerves 
might be in fact as such entirely lost in highly inflamed tissues during arthritis and, hence, can not 
switch their phenotype: Two earlier studies that investigated sensory nerve fibers and nerves positive 
for PGP (protein gene product) 9.5, a cytoskeletal and hence general marker of nerve fibers, in the 
synovium of arthritic rats suggested a general loss of all these nerve fibers in inflamed synovial tissue 
(Hukkanen et al., 1991; Konttinen et al., 1990).  
Yet, there is a technical issue with elucidating sympathetic transition with this type of investigation 
which remains problematic: With the means of immunostaining of ex vivo tissue samples one can not 
precisely detect sympathetic transition in the exact same nerve fiber which in theory should display a 
decrease of adrenergic properties and at the same time gather cholinergic properties, similar to the 
phenomenon in developing sweat glands (Landis et al., 1988; Landis, 1996). This is still a challenge, 
at least by the use of tissue fixation and subsequent immunofluorescent staining of two marker pro-
teins. Even with the means of double immunofluorescence techniques it remains uncertain whether a 
single nerve fiber changed its whole phenotype including functional properties over a given time. For 
example, in certain cardiac sympathetic nerves both phenotypes (adrenergic and cholinergic) seem to 
exist at the same time (Felder & Dechant, 2007). This indicates a co-expression or a transition rather 
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than a switch. A possible solution for overcoming this obstacle might be a mouse strain which ex-
presses two different fluorescent proteins, one under the control of a promoter for TH and the other 
under control of a promoter for ChAT or VAChT, similar to the principle of Felder and Dechant (Felder 
& Dechant, 2007). This might allow detection of both markers in one and the same nerve fiber over a 
certain period of time in vivo. 
4.2 Cholinergic and sympathetic articular innervation in pa-
tients with OA and RA  
In joint-related tissues obtained from patients with OA and RA, so far sensory and sympathetic nerve 
fibers have been investigated (reviewed in (Pongratz & Straub, 2013; Schaible & Straub, 2014)). It 
was demonstrated that in highly inflamed tissues like the synovial tissue a preponderance of sensory 
over sympathetic innervation exists due to suggested reasons discussed in the previous chapter (4.1). 
To check a potential transition of sympathetic nerve fibers in OA and RA, this study focused particular-
ly on a possible cholinergic innervation of tissues relevant to arthritis in the knee and in finger joints of 
OA and RA patients, especially the synovial membrane of finger joints and the knee joint. Due to the 
different surgical needs and procedures in this study, the innervation of the knee could only be tested 
in the synovial tissue while in samples from finger joints, an analysis was possible that differentiates 
between connective (synovial) tissue and bone tissue. 
To date, cholinergic nerve fibers in the human synovial tissue have not been found. In this study, for 
the first time existence of VAChT-positive cholinergic nerve fibers was demonstrated in synovial tissue 
of finger joints (Figure 10A, B) and of the knee (Figure 13A, B) from OA and RA patients. 
In finger joint synovial tissue, density of VAChT-positive cholinergic nerve fibers was significantly high-
er in OA than in RA (Figure 10B), while in knee synovial tissue only a trend was observed (Figure 
13B). Additionally, presence of nerve fibers positive for VIP, an important co-transmitter and marker of 
cholinergic nerve fibers was demonstrated in synovial tissue from finger joints (Figure 10C, D) as well 
as from knee joints (Figure 13C, D). This finding correlates to a study in which VIP+ nerve fibers were 
also demonstrated in the synovial membrane in Sprague Dawley rats (Bjurholm et al., 1990). Sympa-
thetic TH-positive nerve fibers in the synovial membrane of finger joints were also detected (Figure 
12A, B, D). The densities however did not differ between OA and RA (Figure 12E) although a trend 
towards higher densities in OA patients was visible, and a statistical power problem can not be ex-
cluded. 
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Further, in bone tissue of finger joints from OA and RA patients, cholinergic VAChT-positive (Figure 
11E) and VIP-positive (Figure 11G) nerve fibers were detected. However, both VAChT, and VIP densi-
ties did not statistically differ between OA and RA (Figure 11F, H). VIP containing nerve fibers in the 
bone were also found by others who demonstrated the existence of these fibers in the epiphysis and 
in the periosteum of rat bone (Bjurholm et al., 1988; Hill & Elde, 1991; Hohmann et al., 1986) along-
side with sympathetic NPY-positive nerve fibers. Nerve fibers positive for TH and NPY, a known co-
transmitter of sympathetic nerves, are distributed throughout the bone and influence bone turnover 
(Bjurholm et al., 1988; Elefteriou, 2005; Imai & Matsusue, 2002). This is consistent with the sympathet-
ic TH-positive nerve fibers which were also detected in bone tissue of OA and RA patients in this study 
(Figure 12F).The presence of cholinergic VAChT-positive nerve fibers in bone tissue presented in this 
study confirms results from others who just very recently have shown existence of nerve fibers positive 
for VAChT in trabecular bone of the murine femur and in bone defects in an osteoporosis model of the 
rat (Bajayo et al., 2012; Lips et al., 2014). 
The results of this study and the current literature clearly indicate cholinergic innervation of the bone 
and joint in both rodents and humans. In the periosteum, the sympathetic nature of cholinergic inner-
vation has been demonstrated by means of chemical sympathectomy, selective sympathetic gangli-
oectomy, and retrograde staining (Hill & Elde, 1991; Hohmann et al., 1986). However, cholinergic in-
nervation of the femur seems to be controlled by the parasympathetic nervous system indicated by 
retrograde labeling with pseudorabies virus (Bajayo et al., 2012). In other studies, it remains to be 
elucidated whether cholinergic signaling is controlled via the SNS or the parasympathetic nervous 
system. This would be of great value because a cholinergic innervation controlled by the SNS provides 
further evidence of a catecholaminergic-to-cholinergic transition of sympathetic nerve fibers, like in the 
periosteum or in sweat glands. Additionally, activation of a sympathetic cholinergic part of the periph-
eral nervous systems in the bone would require different mechanisms than a parasympathetic cholin-
ergic innervation of bone. However, in respect to current literature, one has to assume that in bone 
cholinergic innervation is used by both, the sympathetic and the parasympathetic nervous system but 
future studies are needed to further elucidate both systems of cholinergic innervation of bone. 
The homeostasis of bone formation and resorption, also termed bone turnover, is tightly balanced by 
the hormone system and the peripheral nervous system. The balance of bone formation, mainly medi-
ated by osteoblasts, and bone resorption achieved by osteoclasts, plays a key role in these processes 
and is relevant to arthritis due to activated osteoclasts in focal bony erosions of affected joints. The 
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two main neurotransmitters released by cholinergic nerve fibers in bone are acetylcholine (ACh) and 
vasoactive intestinal peptide (VIP) (Eimar et al., 2013; Persson & Lerner, 2011). While activation of the 
peripheral sympathetic catecholaminergic nervous system seems to mainly inhibit bone formation and 
to favor bone loss by increased osteoclast formation and differentiation via β2-adrenoceptor signaling 
(Aitken et al., 2009; Cherruau et al., 2003) (reviewed in (Elefteriou, 2005; Straub, 2012; Togari & Arai, 
2008)), an activation of VIP signaling in bone seems to mainly favor bone accrual by directly inhibiting 
osteoclasts through activation of VPAC1 receptors on these cells (Lerner & Persson, 2008). Addition-
ally, VIP counteracts an up-regulation of RANKL by vitamin-D3 and PTH (parathyroid hormone) and a 
decrease of OPG (osteoprotegerin) caused by VitD3 (Lerner & Persson, 2008). Actions of VIP on os-
teoblasts are bimodal because VIP is also able to enhance RANKL production in osteoblasts via main-
ly VPAC2 receptor activation, which in turn leads to up-regulated differentiation and activity of osteo-
clasts (Lerner & Persson, 2008). On the other hand, activation of VPAC2 receptors by VIP on 
osteoblasts leads to increased differentiation of osteoblasts and direct activation of ALP (alkaline 
phosphatase), an important enzyme for bone mineralization and therefore bone formation (Lerner & 
Persson, 2008; Lundberg et al., 1999). 
In addition to the overall promotion of bone formation by VIP signaling in osteoblasts and osteoclasts, 
also direct anti-inflammatory effects of VIP have been reported as reviewed in (Chandrasekharan et 
al., 2013; Delgado & Ganea, 2008; Lerner & Persson, 2008): In microglia, VIP was shown to directly 
influence inflammation by inhibiting the pro-inflammatory cytokines IL-1β, IL-6, IL-12 and TNF, and 
nitric oxides, as well as inhibiting the pro-inflammatory prostaglandine E2 (PGE2) produced by cy-
clooxygenase type 2 (COX-2) in macrophages and dentritic cells (Delgado et al., 2003; Gonzalez-Rey 
& Delgado, 2008). VIP is also locally synthesized by immune cells and in a paracrine/autocrine way of 
signaling seems to direct the immune response towards a rather T helper cell type 2 (Th-2) response 
and to up-regulate T regulatory (Treg) cells (Gonzalez-Rey et al., 2006; Pozo & Delgado, 2004). The 
anti-inflammatory potential of VIP has also been shown in experimental arthritis (Delgado et al., 2001; 
Delgado et al., 2008b) and the use of VIP is proposed as a possible agent for the treatment of RA 
(Chandrasekharan et al., 2013; Delgado et al., 2001; Delgado et al., 2008b; Delgado & Ganea, 2008; 
Gonzalez-Rey et al., 2007). The important role of the VIP receptor VPAC1 has been demonstrated in 
experimental arthritis and in immune cells from RA patients (Delgado et al., 2008a). 
Acetylcholine, the main neurotransmitter of the cholinergic nervous system conveys its signals via a 
variety of receptors, which can be divided into two main groups: Muscarinic, G-protein-coupled seven 
4.3 Transition of nerve fibers from a catecholaminergic to a cholinergic phenotype in vitro 
70 
 
transmembrane domain receptors (type M1 through M5) (Eglen, 2006), and nicotinic ligand gated ion 
channels consisting of a pentamer of different subunits (Lukas et al., 1999). In the context of arthritis, 
especially the homo-pentamer α7-subunit containing nicotinic acetylcholine receptor (α7nAChR) has 
gained attention since its anti-inflammatory potential in inhibiting TNF release from macrophages was 
described (Wang et al., 2003). The anti-inflammatory potential of stimulating the α7nAChR in experi-
mental arthritis (van Maanen et al., 2009a) and in fibroblast like synoviocytes (FLS) from RA patients 
has been shown (van Maanen et al., 2009b). Yet, there is conflicting data regarding these effects in an 
α7nAChR knock-out mouse model (van Maanen et al., 2009b; Westman et al., 2010). Here, the pres-
ence of the α7nAChR in fibroblast like synoviocytes (FLS) is demonstrated (Figure 14), which is in line 
with the results of others who have shown the expression of this receptor in FLS as well as in synovial 
tissue from OA and RA patients (Forsgren, 2012; van Maanen et al., 2009b; Waldburger et al., 2008; 
Westman et al., 2009). Moreover, further parts of the cholinergic machinery, like mRNA for and protein 
of high affinity choline transporter (ChT) and choline transporter like protein (CTL1&2), but absence of 
VAChT mRNA (Beckmann et al., 2015), and presence of ChAT mRNA (Forsgren, 2012; Schubert et 
al., 2012) have been found in the synovial tissue of arthritis patients. Beckman and Lips suggest a 
local non-neuronal cholinergic system (Beckmann & Lips, 2013) similar to the non-neuronal system, 
which has been demonstrated to play a key role in the communication of lymphocytes reviewed by 
Kawashima and coworkers (Fujii et al., 2008; Kawashima & Fujii, 2000; Kawashima & Fujii, 2003; 
Kawashima & Fujii, 2004; Kawashima et al., 2012). 
However, the results of this very study suggest that due to the expression of VAChT, a typical axonal 
marker of cholinergic nerve fibers, and the typical bead like structure of the detected VIP- and VAChT-
positive nerve fibers, also a direct neuronal innervation of the synovial tissue in humans and mice is as 
well possible. 
4.3 Transition of nerve fibers from a catecholaminergic to a 
cholinergic phenotype in vitro 
After the identification of previously unknown cholinergic nerve fibers in joint tissue obtained from ar-
thritic mice and humans, the study aimed to investigate on possible cell types and molecules being 
responsible for the putative transition of the well documented catecholaminergic type of sympathetic 
nerve fibers to a cholinergic type.  
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4.3.1 Transition in the co-culture system of sympathetic ganglia 
For this purpose, the assay of sympathetic ganglia as a model for catecholaminergic sympathetic 
nerve fibers was redesigned as a co-culture system of sympathetic ganglia and cells relevant to arthri-
tis, like OCP cells obtained from BMM, and lymphocytes from inguinal draining lymph nodes. It was 
also intended that fibroblasts obtained from subcutaneous connective tissue in the paw and from the 
periosteum, according to protocols for the isolation of periostal cells and synovial fibroblasts of mice 
(Gao et al., 2006; Kawanami et al., 2009; Korb-Pap et al., 2012; van et al., 2012) were tested, but 
respective cells failed to display the ability of being passaged and transferred to the co-culture cham-
ber slides in a sufficient amount. 
First, sympathetic ganglia without any stimulation or contact to other cells, which reflects the control 
situation, always show a little amount of cholinergic marker expression (reviewed in (Francis & Landis, 
1999)) which was also found in this present study (Figure 16A,B, control). 
The co-culture experiments were divided into two subsets: The first set comprised sympathetic gan-
glia, OCPs and lymphocytes obtained entirely from C57Bl/6 mice (Figure 16A). In the second set, 
OCP cells and lymphocytes were obtained from DBA1/J mice (Figure 16B) in order to test a possible 
mouse-strain specificity. In both subsets of experiments, co-cultures of sympathetic ganglia and osteo-
clast progenitors obtained from healthy control animals displayed a higher frequency of VAChT-
positive cholinergic nerve fibers in the ganglia (Figure 16A,B), while only in the subset with lympho-
cytes obtained from healthy DBA1/J mice, respective experiments displayed this phenomenon (Figure 
16B). This might be due to the presence of immunocompetent cells like resident macrophages or mi-
croglia capable of expressing major histocompatibility complex (MHC) class II molecules (Kiefer et al., 
2001). These might interact with lymphocytes obtained from a different mouse strain and in turn, after 
activation by these lymphocytes, alter expression of cholinergic markers in the neurons of the ganglia 
since glial cells are able to release trophic factors (reviewed in (Hanani, 2010; Jessen, 2004). Interest-
ingly, in co-culture experiments with OCP cells, these cells migrated in a chemotactic fashion towards 
the sympathetic ganglion located in the other half of the well (Figure 15A,B). This confirms results 
from an earlier study showing chemotactic potential of neurotransmitters released by sympathetic 
nerve endings on monocytes (Straub et al., 2000). A direct communication between osteoblasts and 
osteoclasts in co-culture with neurons obtained from the superior cervical ganglion (a sympathetic 
ganglion) has demonstrated α1-adrenoceptor signaling between these two cell types (Obata et al., 
2007; Suga et al., 2010). These findings support the principle concept of this co-culture system using 
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OCP cells together with sympathetic ganglia. A direct effect of bone marrow derived cells has so far 
mostly been described for bone marrow derived stromal cells, which are isolated in a similar way com-
pared to the bone marrow macrophage isolation (Takeshita et al., 2000). For example, stromal cells 
were shown to release chemokines like SDF-1 (stromal derived factor), which are capable of inducing 
dopaminergic neuronal differentiation (Schwartz et al., 2012). Co-culture experiments demonstrated 
an up-regulation of cholinergic properties in neuronal cells when cultured together with heart cells 
(Yamamori et al., 1989), periostal cells (Asmus et al., 2001), and cells obtained from eccrine sweat 
glands (Habecker et al., 1997), which all suggest gp130 class cytokines as being the responsible fac-
tors for cholinergic differentiation. In this study, sympathetic ganglia in co-cultures with OCPs from 
healthy mice displayed an overall higher ratio of VAChT-positive to TH-positive nerve fibers, as well as 
locally enhanced VAChT expression where nerve fibers were in direct contact with OCP cells (Figure 
15, Figure 16). These observations can be interpreted as an effect dependent on a soluble factor re-
leased by OCP cells or a direct contact of sympathetic nerve fibers with extracellular matrix (ECM) 
components produced by OCPs. 
In order to elucidate the differences between OCP cells obtained from healthy control mice and OCPs 
from mice with CIA, cells were subjected to gene expression analysis and proteome profiling. 
4.3.2 Identification of possible transition factors of osteoclast progeni-
tor cells via gene expression analysis 
Gene expression analysis of OCP cells revealed differences in genes that can be generally attributed 
to extracellular matrix related genes, genes related to inflammation like chemokines and cytokines but 
also genes coding for proteins known for transition of sympathetic nerves to a cholinergic phenotype. 
Respective genes are discussed in context of the expression in macrophage/osteoclast lineage of 
cells and their possible influence on the nervous system. 
4.3.2.1 Up-regulated gene transcripts in osteoclast progenitors from healthy 
mice 
4.3.2.1.1 Biglycan (Bgn) 
The most prominent up-regulation in cells from healthy control mice was found for biglycan (BGN) 
(Figure 20). The multiple functions of biglycan, which is regarded as a small leucine rich proteoglycan 
(SLRP) or chondroitin sulfate proteoglycan (CSPG) and is part of the extra cellular matrix (ECM) have 
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recently been reviewed (Nastase et al., 2012): Generally being seen as a rather pro-inflammatory 
signaling molecule, triggering production of interleukin 1beta (IL1b), tumor necrosis factor (TNF) and 
other pro-inflammatory cytokines (via activation of toll like receptors TLR2/4 and purinergic receptor 
P2X7 on macrophages), it also plays an important role in bone homeostasis as it promotes osteoblast 
differentiation by activating receptors of bone morphogenetic proteins and transforming growth factor 
beta. This is supported by the fact that biglycan-deficient mice show an osteoporosis like phenotype 
(reviewed in (Nastase et al., 2012)). Hence, an elevated expression of biglycan by OCP cells in 
healthy mice (as suggested by the gene expression results of this study) would favor bone formation 
in a crosstalk between osteoclasts and osteoblasts, while a lack of biglycan in arthritic animals would 
promote bone loss. It has been shown that activated macrophages are able to express and release 
biglycan (reviewed in (Nastase et al., 2012)). Another report proposes also an anti-inflammatory role 
of biglycan by inhibiting pro-inflammatory effects of the activated complement protein C1q (Groeneveld 
et al., 2005). Further functions of biglycan include its induction of collagen matrix formation in adaptive 
remodeling processes after myocardial infarction (Ahmed et al., 2003; Westermann et al., 2008), 
maintenance of stability of cholinergic synapses at the neuromuscular junction (Amenta et al., 2012), 
transient inhibition of outgrowth of sensory neurons (Lemons et al., 2005), and acting as a neu-
rotrophic factor in neocortical rat neurons as well as activating ventral pallidal-neocortical cholinergic 
neurons in the rat brain (Huston et al., 2000). Thus, it might be a good candidate to induce catechola-
minergic-to-cholinergic transition demonstrated in this study. 
4.3.2.1.2 Tenascin C (Tnc) 
Another up-regulated gene transcript was Tnc (Figure 20), coding for Tenascin C, which belongs to 
the family of ECM glycoproteins and is expressed in bone, cartilage, tendon and nervous system 
amongst other tissues. It has been assigned a variety of functions like modulation of cell adhesion, 
migration and guidance of axonal growth depending on expression of different functional subdomains 
due to alternative splicing (reviewed in (Chiquet-Ehrismann, 2004; Chiquet-Ehrismann & Tucker, 2004; 
Joester & Faissner, 2001)). Expression of tenascin C in the ECM is thought to be up-regulated after 
injuries, during inflammatory and remodeling processes like after myocardial infarction (Milting et al., 
2008). Interestingly, the inflammatory property of tenascin C has been demonstrated in a study in 
which RA patients displayed significantly higher serum concentrations of tenascin C compared to 
healthy controls: The amount of tenascin C positively correlated with the severity of bone erosions in 
affected joints in these patients and therefore was suggested as a possible marker for disease activity 
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in RA (Page et al., 2012). These observations are supported by the fact that tenascin C-deficient mice 
develop a less severe experimental arthritis (reviewed in (Chiquet-Ehrismann et al., 2014)) and dis-
turbed motor coordination properties (Joester & Faissner, 2001). This indicates an important role of 
tenascin C in organizing the ECM during arthritis and different functions in the nervous system. 
4.3.2.1.3 Fibronectin 1 (Fn1) 
Similar to tenascin C, also the gene coding for fibronectin (Fn1) was elevated in OCPs from healthy 
mice (Figure 20). Fibronectin and tenascin C are evolutionarily closely related since they are only 
found in chordates, tenascin C features similar type III functional subdomains like fibronectin, and 
tenascin C is able to modulate fibronectin function (Chiquet-Ehrismann & Tucker, 2011). Yet in contrast 
to tenascin C, which rather inhibits cell adhesion by inhibiting cells to bind to fibronectin and rather 
fosters cell motility (Chiquet-Ehrismann, 2004), fibronectin itself promotes cell adhesion due to the 
high affinity of its RGD motif containing type III domains, which bind to different heterodimers of integ-
rins expressed on cells (Lowin & Straub, 2011). A further important function of fibronectin is the for-
mation of insoluble fibrils, which are a major component of a scaffold for the ECM (Lowin & Straub, 
2011). Importantly, since fibronectin conveys cell adhesion via integrin binding, it plays also a signifi-
cant role for the invasive potential of fibroblasts, because its expression is enhanced in the synovial 
fluid of OA patients and in the synovial lining layer in RA patients (Lowin & Straub, 2011). Thought to 
be produced mainly by non-neuronal cells like Schwann cells, fibronectin is also described as an im-
portant factor for adhesion and guidance of growing or regenerating peripheral nerve fibers (reviewed 
in (Gardiner, 2011; Webber & Zochodne, 2010). In a report investigating the conditioned medium of 
astrocytes stimulated by a cholinergic agonist, fibronectin was shown to be up-regulated, suggesting 
that it plays a role in modeling the ECM of cholinergic neurons (Moore et al., 2009). Since it is a factor 
of ECM in bone, fibronectin also seems to be capable of influencing size and shape of osteoclasts 
(Gramoun et al., 2010). 
4.3.2.1.4 Connective tissue growth factor (Ctgf) 
Another gene related to the ECM and up-regulated in osteoclasts from healthy control mice was Ctgf, 
coding for connective tissue growth factor (Figure 20). It was demonstrated that gene expression of 
Ctgf is involved in the development of the cardiovascular system, of tissue adjacent to bone and carti-
lage, and of certain neurons in the brain (Friedrichsen et al., 2003). Furthermore serum Ctgf was 
shown to be elevated in RA compared to healthy controls as well as in activated RA compared to inac-
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tive RA, and to promote osteoclastogenesis in vitro, suggesting a pro-inflammatory role in RA (Nozawa 
et al., 2009). In a mouse model for hypertrophic cardiomyopathy and heart failure, increased gene 
expression for Ctgf was observed together with tissue inhibitor of metalloproteinase 1 (TIMP-1), fi-
bronectin, tenascin C, and periostin (Tsoutsman et al., 2013), which are also up-regulated in OCPs 
from healthy mice in this study (Figure 20), underlining their importance in ECM remodeling. This 
finding is also supported by the fact that in this study these genes were up-regulated in a similar way 
since they were grouped together by gene clustering in analyzing the microarray results (Figure 21). 
4.3.2.1.5 Tissue inhibitor of metalloproteinase 1 (TIMP-1) 
TIMP-1, a pleiotropic molecule and first member of a family comprising a total of four different TIMPs 
was characterized by its function of inhibiting matrix metalloproteinases (MMPs), which are responsi-
ble for the breakdown of protein based ECM components but also cleavage and, hence, activation or 
deactivation of endogenous signaling peptides (Moore & Crocker, 2012; Ries, 2014). Apart from this 
classical inhibition of MMPs, quite recently additional and alternative functions for TIMP-1 have been 
suggested since not all observed effects by TIMP-1 could be assigned to the well characterized inhibi-
tion of MMPs: In human mesenchymal stem cells (hMSCs) an inhibition of β-catenin signaling in these 
cells was shown to be mediated by a newly discovered receptor for TIMP-1, CD63 (Moore & Crocker, 
2012; Ries, 2014). In addition to this cytokine-like direct signaling pathway, TIMP-1 can also elicit sig-
naling by binding to proMMP-9, one of the main targets of TIMP-1, and subsequent binding of this 
complex to a cell surface-bound receptor, CD44 (Moore & Crocker, 2012; Ries, 2014). Further still 
unknown cell surface receptors for TIMP-1 are being proposed.  
The here described effect of TIMP-1 on sympathetic ganglia in vitro (Figure 18) might be assigned to 
a yet unknown, but direct signaling of TIMP-1 on neuronal or non-neuronal cells present in the ganglia. 
In relation to bone and nervous system, TIMP-1 was shown to be expressed by osteoblasts and oste-
oclasts (Bord et al., 1999; Grassi et al., 2004; Hill et al., 1994), and it has a protective influence on the 
nervous system by ensuring effective myelination (Moore et al., 2011). In RA, it is suggested that in 
synovial fluid the balance between MMP9 and its specific counterpart TIMP-1 is shifted towards 
MMP9, which results in increased breakdown of collagen in the joints (Tchetverikov et al., 2004). Simi-
lar to biglycan, Ctgf, tenascin C and fibronectin, TIMP-1 seems to be involved in the cardiac remodel-
ing of the ECM after heart failure (Vanhoutte & Heymans, 2010). Thus there can be a common reason 
why it was up-regulated together with these genes in OCPs from healthy mice (Figure 20). 
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4.3.2.1.6 Tensin 1 (Tns1) 
Less is known about tensin 1 in respect to an involvement in arthritis and the peripheral nervous sys-
tem, but it is generally regarded as an integrin adaptor protein and, hence, it is involved in cellular 
adhesion processes and seems to be important for invasiveness of tumor cells (reviewed in (Haynie, 
2014)). This again makes sense since tensin was also up-regulated together with other ECM related 
gene transcripts (Figure 20) in OCPs from healthy animals. Expression of tensin has also been shown 
in the podosome-like extensions of osteoclasts, confirming its relevance to cell adhesion processes 
and it was further suggested as a differentiation marker of osteoclasts because of its proposed role in 
fusion processes of osteoclast progenitors (Hiura et al., 1995).  
4.3.2.1.7 Tetraspanin 7 (Tspan7) 
Similar to tensin 1, relatively little is known about tetraspanin 7, especially in regards to arthritis and 
nervous system. Generally, tetraspanins are proteins consisting of four transmembrane domains and 
intracellular and extracellular loops, the latter carrying typical highly conserved motifs which are im-
portant for characteristic dynamic interaction of several tetraspanin molecules and further transmem-
brane proteins, referred to as the ‘tetraspanin-web’ (reviewed in (Levy & Shoham, 2005b; Levy & 
Shoham, 2005a). These processes are important during cell-cell interactions like during communica-
tion of immune cells or in fusion of cells (Levy & Shoham, 2005b; Levy & Shoham, 2005a), which is 
critical in the transition of OCP cells to mature osteoclasts although tetraspanins are thought not to be 
responsible for the fusion themselves but rather to modulate the fusion process (Fanaei et al., 2011). 
4.3.2.1.8 Periostin (Postn) 
Periostin, a matricellular protein, the expression of which was first discovered in the periosteum, pos-
sesses different specific binding domains for tenascin C, collagen type I and fibronectin and it was 
suggested as a modulator of collagen-I-crosslinking, and incorporation of tenascin C hexameres into a 
fibronectin collagen I based ECM, thereby establishing a meshwork (Kii et al., 2010). Mouse strains 
deficient for periostin or tenascin C display similar phenotypes with regions of bone loss, and expres-
sion of periostin and tenascin C in wildtype mice was seen in similar areas, highlighting the functional 
relationship to tenascin C and the ECM in general (Kii et al., 2010). Apart from its promotion of bone 
turnover and development, involvement of periostin has also been shown in remodeling processes in 
the ECM of the myocardium after infarction, in lung tissue after puncture, in lung and respiratory tissue 
in asthmatic and allergic diseases, in skin diseases and wound healing, and in promoting invasiveness 
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of tumor cells and of RA synoviocytes (Conway et al., 2014; Kudo, 2011; You et al., 2014). Interesting-
ly, just like in the transcriptome of OCPs in this study, periostin was also elevated together with TIMP-1 
in a gene expression analysis of an osteoarthritis mouse model (Loeser et al., 2012), again emphasiz-
ing its role in remodeling of the ECM. Additionally, in a very recent study, Shih and colleagues could 
show that periostin also participates in axonal regeneration after injury (Shih et al., 2014). Transcrip-
tional expression of periostin by osteoclasts seems novel since it has so far been shown only by one 
very recent study (Merle et al., 2014). 
4.3.2.1.9 Sparc 
Secreted protein acidic and rich in cysteine (SPARC, also referred to as osteonectin or BM-40) is 
known to be expressed in bone and to have an overall promoting effect on bone accrual, and an inhib-
iting effect on bone resorption, as shown in a SPARC knock-out mouse (Delany & Hankenson, 2009). 
Due to its collagen binding capabilities, SPARC is also involved in ECM assembly and remodeling, 
which is of major importance not only in processes like in bone turnover (Alford & Hankenson, 2006) 
but similar to tenascin C and periostin also in cardiac remodeling (McCurdy et al., 2010; Schellings et 
al., 2004). In addition, a synergistic neurotrophic effect together with BDNF (brain derived neurotrophic 
factor) on retinal ganglion cells (Ma et al., 2010), and an activation of the STAT3 (signal transducer 
and activator of transcription 3) pathway has been reported, leading to increased expression of neu-
ronal markers in medullablastoma cells (Bhoopathi et al., 2011). 
4.3.2.1.10 DC-stamp and OC-stamp 
Both gene transcripts were up-regulated in OCP cells from healthy control mice and code for the two 
seven transmembrane proteins dentrocyte expressed seven transmembrane protein (DC-stamp) and 
osteoclast stimulatory transmembrane protein (OC-stamp). Fusion of OCPs and pre-osteoclasts to 
multinucleated cells is one of several requirements for functional bone resorbing osteoclasts and it 
was shown in vitro and in vivo that expression of both proteins, DC-stamp and OC-stamp, which is 
inducible by RANKL, is required for successful fusion (Miyamoto et al., 2012). Further, OC-stamp, the 
expression of which is assumed to be regulated via protein kinase B/AKT or PKCβ (protein kinase C 
beta) signaling, seems to be not only involved in osteoclast fusion but also in differentiation of osteo-
clasts (Kim et al., 2011). 
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4.3.2.1.11 Oscar 
The expression of Oscar (osteoclast associated receptor) on the osteoclast cell linage in mice and 
humans has been shown previously (reviewed in (Nemeth et al., 2011)). It was demonstrated that 
Oscar activation acts as an important co-stimulus in osteoclastogenesis and that Oscar possesses 
collagen binding domains, suggesting an interaction with the ECM, which Barrow and colleagues in-
deed were able to show (Barrow et al., 2011; Nemeth et al., 2011). In RA, expression of Oscar was 
detected in osteoclasts at focal erosions, in synovial cells and in circulating blood monocytes, the latter 
of which showed enhanced expression in active RA compared to monocytes from RA patients in re-
mission, suggesting a relation between Oscar expression and disease activity (Herman et al., 2008b; 
Crotti et al., 2012). A soluble form of Oscar was demonstrated in similar amounts in synovial fluid from 
RA and OA patients (Crotti et al., 2012) and in serum, in which Oscar was elevated in RA compared to 
healthy controls (Herman et al., 2008b). Here it remains unclear, why Oscar displayed an elevated 
gene transcript expression in OCPs from healthy control mice compared to arthritic animals (Figure 
20). 
4.3.2.1.12 LIF 
Gp130 class cytokines like LIF, OSM, IL-6, CT-1 and CNTF seem to be major players in regulating 
bone mass accrual and resorption in a paracrine fashioned communication between osteoblasts and 
osteoclasts (reviewed in (Auernhammer & Melmed, 2000; Sims & Walsh, 2010; Sims & Johnson, 
2012)). In vivo, LIF leads to an up-regulation of both bone formation and resorption, and it was con-
firmed in vitro that this is mainly due to a direct stimulation of osteoblast lineage cells, which increases 
bone accrual and release of RANK ligand, which in turn indirectly enhances osteoclast differentiation 
and activity, resulting in an overall increased bone turnover ((Palmqvist et al., 2002; Sims & Johnson, 
2012)). Expression of LIF receptor was shown on osteoblasts but not on osteoclasts and, until recent-
ly, expression of LIF by osteoclasts was regarded as not existing (Auernhammer & Melmed, 2000; 
Sims & Walsh, 2010). However, results of this study and two other studies of osteoclast-like cells indi-
cate that OCPs or osteoclast-like cells might under certain circumstances be able to express LIF 
(Gouin et al., 1999; Ota et al., 2013) (Figure 20, Figure 25). In contrast, one study showed up-
regulation of LIF gene expression in total subchondral bone of a chronic joint pain OA model in rats 
(Dawes et al., 2013), but this might be explained by the different animal model of a different disease 
(OA joint pain), and gene expression analysis of total tissue instead of isolated and differentiated 
BMM. Interestingly, in co-culture experiments of osteoclast-like cells and sympathetic ganglion cells, 
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Suga and colleagues could demonstrate an up-regulation of the gp130 cytokine IL-6 upon activation of 
the α1A-adrenoceptor (α1A AR) which is present on osteoclasts (Suga et al., 2010). Hence, it might well 
be that activation of (α1A AR) on osteoclast progenitors by norepinephrine, which is spontaneously 
released by sympathetic ganglia, led to an up-regulation and release of LIF (Figure 20, Figure 25) 
and/or other gp130 class cytokines like OSM (Figure 24), which in turn promoted the well described 
transition from a sympathetic to a cholinergic phenotype in neurons of sympathetic ganglia elicited by 
these cytokines (Bamber et al., 1994; Geissen et al., 1998; Rao et al., 1992; Yamamori et al., 1989). 
4.3.2.2 Up-regulated gene transcripts in osteoclast progenitors from arthritic 
mice 
In contrast to the gene transcripts, which were up-regulated in OCPs from healthy control mice, the 
genes which displayed higher expression in cells from arthritic animals, generally are related to the 
cytokine and chemokine (especially CCL and CXCL) families of molecules, which makes sense given 
that arthritis is an inflammatory disease, in which bone marrow macrophages and osteoclasts are in-
volved (McInnes & O'Dell, 2010; Schett & Firestein, 2010; Firestein, 2003; Straub et al., 2013; 
McInnes & Schett, 2011; McInnes & Schett, 2007). 
4.3.2.2.1 SAA3 
The gene transcript with the highest induction seen in osteoclasts from mice with CIA was SAA3 (se-
rum amyloid A3), which is known to be released from LPS (lipopolysaccharide) stimulated macro-
phages (Meek et al., 1992) alongside with MIP-1a (macrophage inflammatory protein-1a, CCL3) and 
MIP-1b (macrophage inflammatory protein-1b, CCL4) (Meheus et al., 1993), which both also displayed 
enhanced expression in OCPs from arthritic mice (Figure 20). In RA, it was suggested that up-
regulation of SAA3 in the synovium plays a role in the pathogenesis of the disease (Geurts et al., 
2011; O'Hara et al., 2004). Additionally, SAA3 also seems to influence bone homeostasis by affecting 
osteoblast differentiation and osteoclastogenesis (Thaler et al., 2014) as well as having the ability of 
inducing the expression of pro-inflammatory TNF and several matrix metalloproteinases, rendering it 
as a possible marker of disease activity (Connolly et al., 2012).  
4.3.2.2.2 CCL2, CCL7, CCL5, CCL12, CCR5 
The chemokine C-C motif ligand 7 (CCL7), also termed MCP-3 (monocyte chemoattractant protein-3), 
showed the highest up-regulation of several CC and CXC chemokines in OCPs from arthritic mice 
(Figure 20). Similar to CCL2 (MCP-1), CCL7 was shown to enhance formation and differentiation of 
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multinucleated osteoclasts via activation of CCR2 (Binder et al., 2009; Yu et al., 2004) and to be ex-
pressed in synovial tissue of RA patients (Haringman et al., 2006). The importance of these two cyto-
kines in activation and differentiation of osteoclasts was demonstrated in experiments by Binder et al., 
who showed that activation of CCR2 via CCL2 or CCL7 leads to bone loss via an increased RANK 
signaling, which was abrogated in a CCR2 knock-out mouse (Binder et al., 2009). Interestingly, in an 
arthritis mouse model expression of CCL2 and CCL7 in affected joints was shown and inhibition of 
both CCL2 and CCL7 ameliorated the disease severity (Chen et al., 2015). However, several studies 
investigating experimental arthritis in mice indicated that deletion of the receptors CCR2 and CCR5 (a 
chemokine receptor for chemokines CCL5, 3 and 7) unexpectedly did not ameliorate arthritis (Fujii et 
al., 2011; Quinones et al., 2004; Rampersad et al., 2011), and it was even suggested that chemokine 
receptors might have a protective role during arthritis (Doodes et al., 2009; Fujii et al., 2011; Quinones 
et al., 2004; Rampersad et al., 2011). This is in line with several clinical trials in which treatment of RA 
patients by chemokine receptor antagonists failed to improve the disease (Asquith et al., 2015; Lebre 
et al., 2011). However, the chemokines CCL2 and CCL7 were implicated to also play a role in the 
nervous system, since they were shown to promote dopaminergic differentiation (Edman et al., 2008) 
and activity (Guyon et al., 2009; Semple et al., 2010). Further, CCL2 was also shown to influence no-
ciception in dorsal root ganglia (Biber & Boddeke, 2014; Jung et al., 2008), to be co-expressed with its 
receptor CCR2 in certain dopaminergic and cholinergic neurons of the CNS (Banisadr et al., 2005; 
Melik-Parsadaniantz & Rostene, 2008), and to be expressed in sympathetic ganglia upon axotomy 
(Schreiber et al., 2001). Hence it might well be that CCL2 or even other chemokines released by 
OCPs from arthritic mice support expression of the existing dopaminergic phenotype of most of the 
neurons in sympathetic ganglia and prevent a possible up-regulation of cholinergic markers like in co-
culture experiments with OCPs from healthy control mice (Figure 16). CCL12 (or MCP-5, monocyte 
chemoattractant protein-5) is structurally and functionally very closely related to CCL2 (MCP-1) (Sarafi 
et al., 1997), since they signal via the same receptor CCR2. Interestingly they both are induced under 
hypoxia in astrocytes (Mojsilovic-Petrovic et al., 2007), and it was also suggested that CCL12 has a 
decisive role in joint development (Longobardi et al., 2012), highlighting an involvement in the skeletal 
and nervous system. 
4.3.2.2.3 CCL3, CCL4, CCL6, CCL8, CXCL2, CXCL3 
Similar to this study (Figure 20, Figure 28), expression of CCL3/MIP-1a (macrophage inflammatory 
protein-1a) was also detected in supernatants of OCPs obtained from BALB/C mice and from a murine 
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osteoclast-like cell line (Lee et al., 2007; Yu et al., 2004). Further, CCL3 was shown to foster differenti-
ation and motility but not activity of osteoclasts (Fuller et al., 1995; Oba et al., 2005; Yu et al., 2004). 
The here demonstrated presence of CXCL2/MIP-2a (macrophage inflammatory protein-2a) expressed 
by OCPs (Figure 20, Figure 28) confirms earlier studies which show that CXCL2 gene and protein 
expression in OCPs treated with RANKL or LPS is enhanced and it was suggested that CXCL2 in-
creases osteoclastogenesis (Ha et al., 2010; Ha et al., 2011; Tanaka et al., 2013). Since elevated 
presence of CXCL2 was shown in synovial fluid and serum from RA patients compared to OA (Ha et 
al., 2010), and the deletion of only CXCR2 (the main receptor of CXCL2) but not any other chemokine 
receptors improved autoantibody-induced arthritis, the CXCL2/CXCR2 and CXCL10 signaling path-
ways remain promising targets for future studies and clinical trials in RA (Asquith et al., 2015; Jacobs 
et al., 2010). In the CNS and in immune cells, expression of CXCR2 has been shown (reviewed in 
(Veenstra & Ransohoff, 2012)), but no expression in sympathetic ganglia has been described yet alt-
hough CXCL2/CXCR2 axis signaling seems to play a key role in recruiting immune cells to sensory 
ganglia (Stock et al., 2014). Not so much is known about CXCL3, which is another ligand for CXCR2 
(Jacobs et al., 2010) and hence might display similar properties as CXCL2. 
CCL6, also known as C10/MRP-1, has been demonstrated to be produced by BMM treated with either 
IL-4, GM-CSF, or M-CSF (Orlofsky et al., 1994), and since its expression was also shown in microglia, 
it was suggested that CCL6 might also be involved in immune-system-CNS crosstalk (Kanno et al., 
2005). 
Similar effects of CCL4 (MIP-1b) and CCL3 (MIP-1a) were suggested in bone marrow cells from multi-
ple myeloma patients, as they both enhanced osteoclast activity by an elevated secretion of RANKL 
and both signal via the same receptor CCR5 (Abe et al., 2002). Gene expression analysis in a human 
osteoclast cell line indicated up-regulation of CCL4 along with CCL2, CCL3 and CCL5 upon stimula-
tion with M-CSF and RANKL (Morrison et al., 2014). Interestingly, in a study examining RA patients 
during anti-TNF therapy, a decrease of the chemokines CCL2, CCL4 and CXCL10 in the patients’ 
blood was observed within the initial two weeks of treatment (Eriksson et al., 2013). In another study, 
presence of CCL2 (MCP-1), CCL5, CCL7 and CCL8 (MCP-2) alongside CCR5 (a receptor for CCL3 
and CCL4) was demonstrated in synovial tissue of RA patients (Haringman et al., 2006). 
4.3.2.2.4 IL1-α, IL1-β, TNF, MMP-8, Marco 
Elevated expression of TNF, IL-1α and IL-1β, as found in OCPs of arthritic mice in this study (Figure 
20) was not surprising since these cytokines are known to be expressed in the bone marrow (Van 
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Bezooijen et al., 1998) and by (bone marrow) macrophages (Braun & Zwerina, 2011; Kwan et al., 
2004; Li et al., 2003), and are up-regulated in animal models of arthritis and in RA (Braun & Zwerina, 
2011; Schett, 2011). In general, the net effect of these three cytokines is regarded as rather pro-
inflammatory and pro-osteoclastogenic, leading to enhanced bone loss and erosions in arthritis (Braun 
& Zwerina, 2011; Schett, 2011). 
Although circulating levels of matrix metalloproteinase 8 (MMP-8), a collagenase, were associated 
with a higher risk of mortality due to respiratory diseases in patients with RA (Mattey et al., 2012), 
knock-out models for MMP-8 showed exacerbation of experimental arthritis, suggesting also a protec-
tive role for MMP-8 in arthritis (Cox et al., 2010; Garcia et al., 2010). 
Marco, a transmembrane class A scavenger receptor on macrophages (Kraal et al., 2000), was found 
to be a receptor especially for bacterial compounds such as LPS, but it also recognizes whole living or 
heat killed bacteria (Chen et al., 2010; Kraal et al., 2000; Sankala et al., 2002) such as mycobacterium 
tuberculosis (Bowdish et al., 2009), which was also used for the induction of experimental arthritis in 
this study (2.3). This might be a reason for the up-regulated gene expression of Marco in OCPs from 
arthritic animals (Figure 20). 
To summarize the results of the gene expression analysis in this study, OCPs obtained from healthy 
control mice displayed an up-regulation of genes which apart from LIF, a known factor for cholinergic 
transition, are related to remodeling processes of the ECM (TIMP-1, Bgn, Tnc, Fn1, Ctgf, Tspan7, Tns, 
Sparc, Postn), but some feature also influences on the nervous system (Bgn, Tnc, Fn1, Sparc, Postn) 
or osteoclast fusion processes (Tns, Tspan7, Dcstamp, Ocstamp). On the other hand, OCPs obtained 
from mice with CIA, display an up-regulation in gene transcripts which mainly code for inflammatory 
cytokines and chemokines, some of which also play a role in neuronal differentiation (CCL2, CCL7). 
These results suggest that LIF, possibly augmented by ECM related molecules, enhanced expression 
of cholinergic markers in co-culture experiments with OCPs from control mice, while up-regulated 
chemokines might have inhibited this transition in experiments with OCPs from CIA mice (Figure 16). 
Additionally, the fusion process of OCPs seems to be differently regulated in healthy and arthritic mice. 
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4.3.3 Identification of possible transition factors of osteoclast progeni-
tor cells by proteome analysis 
Following gene expression analysis, supernatants from OCPs obtained from healthy control and ar-
thritic mice were first subjected to semi quantitative cytokine profiling, followed by quantitative ELISA 
measurements of promising candidate proteins.  
In the cytokine profile (I) (Figure 22), most of the investigated proteins displayed relative weak signal 
intensities between 1 and 20%. Notably, if there was a difference, signals were consistently higher in 
samples from CIA compared to control. This is reasonable for cytokines like interleukin 1α/β, 6, 7, 
12p70, 17, 23, and, in part, 27 which are generally regarded as pro-inflammatory and present in in-
flamed joints (reviewed in (Firestein, 2003; Herman et al., 2008a; McInnes & Schett, 2007)) but not so 
much for interleukins 4, 10 or 13 which were shown to be down-regulated under inflammatory condi-
tions and are regarded as rather anti-inflammatory cytokines (reviewed in (Firestein, 2003; Herman et 
al., 2008a; McInnes & Schett, 2007)). Interestingly, no difference in TNF, TIMP-1 expression was seen 
with the profiling technique, which might be a problem of low statistical power (n=4 vs. n=4). C-C and 
C-X-C motif chemokine protein expression levels were generally higher, which makes sense since 
many of these chemokines play a role in the monocyte/macrophage lineage of cells. Strong protein 
expression (more than 20% relative signal intensity) was detected for CCL2, 3, 4, 5 and CXCL1, 2, 10 
and 12 (cytokine profile (II) Figure 23). 
First, TIMP-1 and LIF, which displayed elevated gene expression were assayed with ELISA, followed 
by OSM, which was not up-regulated in the gene expression analysis but is a known gp130 class cy-
tokine for sympathetic transition and normally present in bone (see 4.3.2.1.12). Strikingly, TIMP-1, LIF 
and OSM were indeed present in low levels in the supernatants of both, control and CIA OCPs, with 
TIMP-1 and OSM showing higher levels in supernatants from control OCPs (Figure 24). LIF was also 
present in of both supernatants but at equally low levels (Figure 25). The significance of TIMP-1 and 
LIF in bone and the nervous system has been discussed above (4.3.2.1.5 and 4.3.2.1.12, respective-
ly). 
So far an expression of OSM in fully developed osteoclasts has not been reported (reviewed in 
(Heymann & Rousselle, 2000; Sims & Walsh, 2010)), but just recently it has been found that OSM can 
be expressed not only in osteoblasts and osteocytes (both mesenchymal cells) but also macrophages 
(hematopoietic cells) (Guihard et al., 2015). Since OCPs in this study were shown to express OSM 
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(Figure 24), and these OCPs were generated from BMM (hematopoietic cells), it might well be that 
different stages of developing osteoclast precursors indeed do express OSM protein. As a special 
gp130 class cytokine, OSM seems to play an ambivalent role in bone since it uniquely mediates its 
signals through two different receptor combinations (gp130+OSM receptor complex, gp130+LIF recep-
tor complex) which are expressed on different bone cells (osteoblasts, osteocytes), acting directly on 
osteoblasts and indirectly on osteoclasts via osteoblasts (reviewed in (Heymann & Rousselle, 2000; 
Sims & Walsh, 2010)): It was demonstrated that OSM enhances osteoclast differentiation and activity 
(Richards et al., 2000), which was shown to be an indirect effect of increased RANKL expression in 
osteoblasts which in turn stimulated osteoclasts (Palmqvist et al., 2002; Sims & Walsh, 2010). Addi-
tionally, OSM also fosters osteoprotegerin (OPG) expression which favors bone formation (Palmqvist 
et al., 2002). To make things even more complex, it was suggested that OSM, when signaling via the 
OSM receptor complex, leads to enhanced bone turnover via RANKL induced bone resorption and 
OPG induced bone formation (Walker et al., 2010). However, there seems to be an independent path-
way mediated via the LIF receptor complex leading to enhanced bone formation by inhibition of scle-
rostin in osteoblasts (Walker et al., 2010). Interestingly and in line with observations in this study, OSM 
up-regulation coincided also with an increase in TIMP-1 expression (Figure 24), which was also seen 
in human cardiac myocytes and fibroblasts (Weiss et al., 2005), in human synovial lining cells (Gatsios 
et al., 1996) and osteoblasts (reviewed in (Heymann & Rousselle, 2000)) and it was suggested that an 
up-regulation of TIMP-1 might be counter-regulatory to limit tissue destruction by increased MMP ac-
tivity in heart remodeling (Weiss et al., 2005). In the joint however, OSM was shown to be mainly pro-
inflammatory, enhancing tissue damage, although the net effect depends on the local receptor constel-
lation for OSM and corresponding target cells which mediate the effects (Hui et al., 2003; Langdon et 
al., 2000; Moran et al., 2009; Richards, 2013; Rowan et al., 2003). The influence of OSM and other 
gp130 class cytokines on sympathetic ganglia has been discussed (4.3.2.1.12), and the elevated con-
centration of OSM in supernatants from control OCPs might be a reason for the observed increase in 
VAChT/TH ratio in sympathetic ganglia in co-culture with control OCPs (Figure 16), since an elevated 
expression of LIF in OCPs from control mice as suggested by gene expression analysis (Figure 20) 
could not be demonstrated by measuring LIF protein (Figure 25). The expression of LIF protein by 
OCPs however is novel (see also 4.3.2.1.12). The protein expression of several macrophage and os-
teoclast related chemokines (CCL2/MCP-1, CCL7/MCP-3, CCL3/MIP-1a, CXCL2/MIP-2a, 
CCL5/RANTES and CXCL10) was confirmed with ELISA (Figure 27, Figure 28, Figure 29). However, 
only CCL5/RANTES displayed higher protein expression in OCPs generated from CIA mice, rendering 
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this specific chemokine as a possible inhibitor of the sympathetic transition seen in co-cultures with 
OCPs from healthy controls (Figure 16), similar to CCL2 and CCL7, which were described to enhance 
dopaminergic properties in neurons (see 4.3.2.2.2). The proteins periostin and CXCL12 were rated as 
non-detectable since they displayed sub-standard signals in the ELISA assay (Figure 30). The signifi-
cance of all these factors in bone and in the nervous system has already been discussed above (see 
4.3.2). However, one can not exclude that other soluble factors supported the observed cholinergic 
transition of sympathetic ganglia in co-culture with OCPs. For example, the expression of Satb2 was 
shown to be crucial in the cholinergic transition of sympathetic neurons and at the same time it is ex-
pressed by osteoblast lineage cells, and is involved in skeletal development and osteoblast differentia-
tion (Apostolova et al., 2010; Dobreva et al., 2006). Future studies will be needed to further clarify the 
observed differences. 
4.3.4 Identification of possible transition factor DNA binding sites by 
genomic analysis 
In this study, progesterone was found to augment LIF induced cholinergic transition of sympathetic 
ganglia (Figure 17), which is not in contrast to earlier literature which suggested that the glucocorti-
coid corticosterone and the mineralocorticoid aldosterone but not the sex steroid progesterone inhibit 
an up-regulation of cholinergic markers in sympathetic ganglia in culture (McLennan et al., 1984). This 
inhibition of cholinergic transition was blocked by RU38486 (Mifepristone), a glucocorticoid receptor 
and progesterone receptor antagonist (Hendry et al., 1987). It was suggested that non-neuronal cells 
present in the ganglia are in vivo controlled by steroids, which prevents them from releasing soluble 
factors that would elicit cholinergic switching of neurons in the ganglia (Fukada, 1980; McLennan et 
al., 1980). These inhibitory effects of glucocorticoids have been later confirmed by others (Berse & 
Blusztajn, 1997) and presence of progesterone and its receptor has been demonstrated in neurons 
(Chan et al., 2000). It was further suggested that within the VAChT cholinergic gene locus there exists 
a response element for glucocorticoid receptors (Cervini et al., 1995) which is confirmed by results of 
this very study, predicting the presence of progesterone receptor and glucocorticoid receptor binding 
sites in promoter regions of VAChT (see 3.6). Quite recently, it was also shown for the sex steroid 
estrogen to up-regulate cholinergic ChAT transcriptome in a neuronal cell line in vitro (Yamamuro & 
Aizawa, 2010). These observations and the presence of progesterone in the medium of ganglia exper-
iments, a possible yet unknown local production of progesterone by BMM/OCPs and its presence in 
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the synovial fluid of OA and RA patients (Figure 26) might possibly also be supporting an up-
regulation of cholinergic markers in sympathetic peripheral nerve fibers. 
4.3.5 Transition of sympathetic ganglia by stimulation with single mol-
ecules 
To investigate possible influences of candidate molecules on frequency of the cholinergic marker 
VAChT in sympathetic nerve fibers, these molecules were tested in stimulation experiments with sym-
pathetic ganglia. In line with previous work of others (see 4.3.2.1.12), expectedly LIF increased the 
VAChT/TH ratio in nerve fibers of sympathetic ganglia (Figure 17). Interestingly, this effect was sup-
ported by the presence of progesterone, which has been discussed above (4.3.4). Also biglycan and 
TIMP-1 enhanced the frequency of cholinergic immunoreactivity in sympathetic ganglia, which might 
render novel functions of these molecules, which were discussed in 4.3.2.1. RGDS and fibronectin 
displayed an effect on the morphology of nerve fiber growth which supports their influence in adhesion 
processes (discussed in 4.3.2.1.3). 
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5 Conclusion 
First, this study confirms earlier observations that in highly inflamed regions of the joint like the synovi-
um and near focal bony erosions, sympathetic TH-positive nerve fibers are lost. This was shown in 
earlier studies of RA patients and in experimental arthritis of mice (CIA) in this study. A suspected 
transition to a cholinergic phenotype of sympathetic nerve fibers was not demonstrated in these re-
gions. This phenomenon of cholinergic transition is only known for sympathetic catecholaminergic 
nerve fibers and not for sensory nerve fibers, which are often increased in highly inflamed tissue. 
Secondly and unexpectedly, an increase of cholinergic, VAChT-positive nerve fibers in rather healthy 
tissue (skin and muscle) was detected at the same time (day 35 p.i.) in experimental arthritis at which 
TH-positive nerve fibers were lost. This supports the concept by Pongratz and Straub who suggested 
an overall change of innervation and conditions in inflamed joints in CIA at this very point of time 
(Pongratz & Straub, 2013), marking a transition from acute to chronic inflammation. In concordance 
with this observation, cholinergic VAChT-positive fibers were more prevalent in joint tissue from OA 
patients compared to RA, with OA being generally considered as a disease with a lower degree of 
local and systemic inflammation. Furthermore, cholinergic transition of sympathetic nerve fibers could 
be induced in vitro, but only by bone marrow derived cells from healthy control and not from arthritic 
animals, supporting the above mentioned results. Importantly, the possibility of a direct innervation by 
VAChT-positive and VIP-positive cholinergic nerve fibers in the synovial tissue of RA and OA patients 
and humans in general was demonstrated here for the first time. 
Thirdly, in addition to previously known transition factors LIF and OSM, an influence on transition by 
ECM-related factors, progesterone, and possibly chemokines was demonstrated. In respect to exten-
sive work of others and results of this very study, early concepts of static and purely adrenergic or 
cholinergic nerve fiber phenotypes seem obsolete. 
In conclusion, presence of cholinergic innervation would provide the required neurotransmitters ACh 
and VIP for anti-inflammatory signaling elicited by local expression of α7nAChRs and VIP receptors on 
immune cells and synovial cells, which would support a therapy concept for arthritis in enhancing and 
exploiting these anti-inflammatory signaling pathways. 
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6.3 Abstract 
Objective. Density of sympathetic nerve fibers decreases in inflamed arthritic tissue, which is tested by 
detection of tyrosine-hydroxylase (TH, key enzyme of catecholamine synthesis). However, under cer-
tain circumstances like during the innervation phase of developing sweat glands or in periosteum, 
sympathetic nerve fibers can change phenotype from catecholaminergic to cholinergic. Therefore, the 
observed loss of sympathetic nerve fibers in arthritis might be due to undetectable TH. The aim of this 
study was to investigate a possible catecholaminergic-to-cholinergic transition of sympathetic nerve 
fibers in synovial tissue of animals with collagen induced arthritis (CIA), and patients with rheumatoid 
arthritis (RA) and osteoarthritis (OA), and to find a possible factor responsible for the transition. 
Methods. Nerve fibers in samples from RA and OA patients as well as in samples from mice were 
detected by immunofluorescence towards TH (catecholaminergic), vesicular acetylcholine transporter 
(cholinergic) and vasoactive intestinal peptide (cholinergic). In-vitro co-culture experiments with sym-
pathetic ganglia and lymphocytes or osteoclast progenitors (OCPs) were designed to find stimulators 
of catecholaminergic-to-cholinergic transition including gene expression and proteome profiling of 
osteoclast progenitor cells. 
Results. In mouse paws, an increased density of cholinergic relative to catecholaminergic nerve fibers 
appeared towards day 35 post immunization, but most nerve fibers were located in healthy joint-
adjacent skin or muscle and almost none in inflamed synovial tissue. In humans, cholinergic fibers 
were more prevalent in less inflamed OA than in highly inflamed RA synovial tissue. Co-culture of 
sympathetic ganglia with OCPs obtained from healthy but not from arthritic animals induced catechol-
aminergic-to-cholinergic transition. OCP mRNA microarray data from healthy animals indicated that 
leukemia inhibitory factor (LIF) is a candidate transition factor, which was confirmed in ganglia experi-
ments, particularly, in the presence of progesterone. Gene expression and proteome analysis of OCPs 
furthermore suggested an up-regulation of extracellular matrix related genes and proteins in addition 
to oncostatin M (OSM) in OCPs from healthy animals and up-regulation of pro-inflammatory chemo-
kines in cells from arthritic mice. Study key results have been recently published (Stangl et al., 2015). 
Conclusion. In humans and mice, catecholaminergic-to-cholinergic sympathetic transition happens in 
less inflamed tissue but not in inflamed arthritic tissue or under inflammatory conditions in-vitro. Under 
healthy conditions, presence of cholinergic sympathetic nerve fibers may support the cholinergic anti-
inflammatory influence recently described.  
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